Background {#Sec1}
==========

The worldwide prevalence of chronic diseases, such as cardiovascular disease, cancers, stroke and diabetes is rising \[[@CR1]\]. Low cardiorespiratory fitness is strongly associated with chronic diseases and premature mortality \[[@CR2]--[@CR7]\]. To alleviate the health and economic burden associated with low cardiorespiratory fitness, health guidelines across the world recommend individuals undertake regular exercise \[[@CR1]\].

Exercise training can increase cardiorespiratory fitness and decrease chronic disease via a number of mechanisms \[[@CR7]\]. Adaptations include improvements to cardiac size, stroke volume (increase in volume of blood pumped from the left ventricle), cardiac output (volume of blood pumped from the heart per minute), pulmonary blood flow and respiratory function, supply of oxygen-rich blood to working muscles (increased number of capillaries and blood volume), muscle mitochondrial function and content, oxidative enzyme capacity, vascular wall health and function, and biomechanical efficiency \[[@CR2], [@CR7]\]. It has been suggested that improvements in cardiorespiratory fitness in response to exercise training varies greatly between individuals, with some people responding well or very well ('responders' or 'high-responders') to exercise training, whereas others only have mild increases in their cardiorespiratory fitness following similar exercise training ('low-responders') \[[@CR4], [@CR5], [@CR8]--[@CR11]\]. Importantly, these responses need to be compared to within-subject random variation to ascertain true inter-individual differences \[[@CR12]\]. The ability to change cardiorespiratory fitness is a multifactorial trait influenced by environmental factors (such as exercise training) and genetic factors \[[@CR4], [@CR5], [@CR11]\]. Considering cardiorespiratory fitness is one of the best integrative predictors of morbidity and mortality risk, it may be important to understand how genetics predict the variability in response to exercise training. This knowledge could lead to targeted personalised exercise therapy to decrease the burden of chronic disease.

The gold standard measure for cardiorespiratory fitness is maximal oxygen uptake (VO~2max~), which is quantified as the maximal amount of oxygen the body can use in 1 min, during dynamic work with large muscle mass \[[@CR13]\]. Research into human variation of VO~2max~ was first undertaken over forty years ago, with several authors identifying a strong genetic influence on VO~2max~ in twins \[[@CR14], [@CR15]\]. Subsequent studies have identified significant familial aggregation for VO~2max~ trainability. For example, authors have found greater variance between pairs of monozygotic (MZ; identical) twins than within pairs of twins for VO~2max~ training response after standardized aerobic training interventions \[[@CR16], [@CR17]\]. The strongest evidence to date on this topic was found in the HEalth, Risk factors, exercise training And GEnetics (HERITAGE) family study \[[@CR18]\]. Four hundred seventy-three Caucasian adults from 99 nuclear families completed 20 weeks of Moderate Intensity Continuous Training (MICT). The average increase in VO~2max~ was 400 mL O~2~/min, with a range from − 114 to + 1097 mL/min. This difference was two and half times greater between families than within families, with a 47% heritability estimate for VO~2max~ training response \[[@CR18]\]. A major limitation from these findings, however, is there was no comparator control group.

Since this familial longitudinal research, the Human Genome Project completed sequencing of the human genome resulting in significant advancements in genetic analysis capabilities. This led to a better understanding of genetic variations of large populations. Analyzing genetic variants on a population level using techniques such as candidate gene analysis, GWAS, whole genome and exome sequencing and RNA expression analysis (RNA-seq, or microarrays) has resulted in the possibility of developing 'personalized genomics'. This aims for biological profiling to provide more effective health management and treatment \[[@CR5]\]. However, research in the field of exercise genomics it still in its infancy and much work is needed before genomic tools could be utilized to personalize exercise training programs \[[@CR19]\].

The aim of this study was to systematically review the literature and identify genetic variants that have been associated with VO~2max~ trainability following an aerobic exercise training intervention. Given the infancy of this research field, results should only be used to provide the basis for future research. This research should aim to confirm previous findings and investigate mediators that can influence gene expression. Importantly, future genetic studies in this area should attempt to investigate the physiological functions that contribute to improving VO~2max~ training response and overall health outcomes. Findings from ongoing research may assist clinical professionals to provide personalized evidenced-based medicine centered on phenotype, contributing to the fight against chronic disease.

Methods {#Sec2}
=======

A comprehensive search of four databases (PubMed, Embase, Cinahl, Cochrane) was completed from their inception until October 2016. Studies focusing on genes and their VO~2max~/VO~2peak~ response to supervised aerobic training were sought with the following search terms: genetic profiling, polymorphism, single nucleotide polymorphisms, SNPs, genetic variants, predictor genes, trainability, endurance training, cardiovascular fitness, cardiorespiratory fitness, VO~2max~, VO~2peak~, aerobic power, aerobic fitness, aerobic capacity. A full list of search terms can be found at the end of this review.

Two authors (CW and JC) agreed on the criteria for inclusion. Articles were incorporated if they were: original, peer-reviewed research; included an aerobic intervention, with minimum 75% supervision; included genetic variant testing; included a maximal VO~2max~/~peak~ using direct gas analysis from an incremental test (pre and post intervention); conducted on humans; and written in English.

Using an extraction grid, one author (CW) conducted the initial screening analysis. After removing duplicates and scanning the titles and abstract of articles, those meeting the inclusion criteria were reviewed. Data recorded from the review consisted of the author's name and place of study, study design, study sample, tissue source, genotyping method used, gene and variant examined, genotype, gene expression (if examined), intervention used, possible mediators (such as medications and health concerns), and the influence of the genetic variant investigated on VO~2max~ change. Further articles were retrieved from snowballing included articles from their reference lists. Articles included in the review are in Table [1](#Tab1){ref-type="table"}.Table 1Summary of included articlesAuthor, Year, CountryGene/s tested for VO~2~max trainabilityStudy DesignStudy SampleTissue sourceMethod for GenotypingInterventionXu, 2015, China*ALAS2*Single group, longitudinal. VO~2max~ and venous blood samples taken pre & post intervention.*N* = 244 healthy Chinese males; 18-22 years (20 ± 1.76); wt 65.06 ± 9.59 kg; ht. 174.37 ± 6.16 cm. *N* = 72 randomly selected for HiHiLo training (69.8 ± 7.8 kg and 177.93 ± 5.26 cm).Peripheral blood leucocytesPCR protocol + separation on polyacrylamide gel4 weeks; supervised HiLo training in hypoxia-training centre. Hi = bicycle ergometer for 30 mins at 75% VO~2max~, in 15.4% O~2~ concentrated environment, 3×/week for 4 weeks. Lo = same training but at lower elevation.Yu, 2014, China*APOE*Single group, longitudinal. VO~2max,~ anthropometric and serum levels tested pre & post intervention.*N* = 360; 180 Chinese males and females; age 32.8 ± 11.9 yrs.; BMI 25.4 ± 5.6 kg/m^2^ M; BMI 26 ± 6.2 kg/m^2^ F; no health concerns; inactive.Peripheral blood leucocytesPCR-(polymerase chain reaction)-RFLP (restriction fragment length polymorphism) assay6 mths; progressive; supervised aerobic training; 60--85% VO~2max~.Zarebska, 2014, Poland*GSTP1*Single group, longitudinal. VO~2max~, HR~max~, VE~max~, AT and body composition tested pre & post intervention; balanced diet prior to intervention (2000 kcal)*N* = 66 Polish females; 19--24 yrs.; BMI 21.8 ± 2.1 kg/m^2^; no health concerns; inactive; no supplements or medications; non-smokers.Buccal cellsTaqMan allelic discrimination assay using qPCR3 mths; supervised; progressive MICT; 3×/wk.; 50--75% HR~max~; 30--60 min.Ghosh, 2013, Singapore*GWAS*Retrospective, single-group longitudinal. V0~2max~ tested pre & post intervention.HERITAGE WHITES: *n* = 473 Caucasians; 230 male & 243 females; no major health concerns; inactive.Lymphoblastoid cell linesIllumina Human CNV370-Quad Bead ChipsHERITAGE: 20 wks; supervised; progressive MICT; 3×/wk.; 55--75% VO~2max~; 30--50 min.Bouchard, 2011, USA*GWAS*Retrospective HERITAGE: Single group, longitudinal; VO~2max~ tested pre & post intervention. DREW: RCT; VO~2max~ tested pre & post intervention. STRRIDE 1 & 2: RCT; VO~2max~ tested pre & post intervention.HERITAGE WHITES: n = 473 Caucasians (252 women); 17--65 yrs.; inactive; no major health concerns\
HERITAGE BLACKS: *n* = 259 (177 women); 17--65 years; inactive; no major health concerns\
HERITAGE average age = 35.7 ± 14.5 yrs., BMI 25.8 ± 4.9 kg/m^2^.\
DREW study: *n* = 464 overweight or obese postmenopausal women; inactive; no major health concerns.\
STRRIDE 1 study: M&F; 40--65 yrs.; inactive; overweight, dyslipidemic and postmenopausal (F).\
STRRIDE 2 study: 18--70 yrs.; inactive; overweight, dyslipidemic. *N* = 183 for STRRIDE 1&2 studies.Lymphoblastoid cell linesIllumina Human CNV370-Quad Bead ChipsHERITAGE\
20 wks; supervised; progressive, MICT; 3×/wk.; 55--75% VO~2max~; 30--50 min.\
DREW: 6 mths; supervised; exercise groups: 4, 8 or 12 kcal/kg/week (MICT); 3-4×/week; progressive training intensity started at 50% VO~2max~. Each group expended 4 kcal/kg/week for first week.\
Group 1: maintained 4 kcal/kg/week for 6 months. Group 2: increased by 1 kcal/kg/week until 8ckal/week reached -- maintain for remaining time. Group 3: increased by 1 kcal/kg/week until 8ckal/week reached -- maintain for remaining time.\
STRRIDE 1: 8--9 mths; supervised exercise sessions. Three groups: 1. High-amount/vigorous intensity exercise (170 min/week/2000 kcal/week) or the calorie equivalent of jogging for \~20 miles per week at 55--85% VO~2max~.\
2. Low amount/vigorous-intensity exercise/1200 kcal/week (\~120 min/week) or the equivalent of 12 miles/week for jogging at 65--80%.\
3. Low amount, moderate intensity exercise (1200 kcal/week (170 min/week) or the equivalent of 12 miles/week at 40--55% VO~2max~.\
STRRIDE 2: 8--9 mths; supervised; four groups:\
1: Aerobic training -- 1300 cal -- 65-80%; 2: Resistance training only with 3 sets of 12--15 reps 3 x /week. 3: Combination of the first 2 protocols; 4: High anaerobic training -- 2200 cal -- 3 x week -- 65-80%. First 2--3 months 'ramp up period'. Following 6 mths using appropriate protocol.McKenzie, 2011, USA*AKT*Single group, longitudinal. VO~2max~ tested pre & post intervention; dietary stabilisation.*N* = 51 M and 58 F Caucasians; 50--75 yrs.; no major health concerns; non-smoking; BMI \<37; haematocrit \>35; BP between 120/80 but less than 160/100 mmHg; at least one lipid abnormality; not any medication for blood pressure, cholesterol or glucose; F post-menopausal for at least 2 years (stable HRT or non HRT); inactive.Peripheral blood leucocytesTaqMan allelic discrimination assay using qPCR24 wks; supervised; progressive MICT; 3×/wk.; 50--70% HRR; 20--40 min.Thomaes, 2011, Belgium*AMPD1; GR; CNTF*Retrospective, single group, longitudinal. VO~2peak~ tested pre & post intervention.N = 935 coronary artery disease patients (CAD); 76 females; Caucasian; age 56 ± 0.3 yrs.; BMI 25.8 ± 0.1 kg/m^2^; 5% smokers; 85% cardiac medications; 5% diabetes; 27% hypertension.Peripheral blood leucocytesInvader TM assay (third wave technologies)3 mths; supervised; 2-3×/wk.; 80% HR~max~; 90 mins/session.Onkelinx, 2011, Belgium*NOS3; Catalase; VEGF; Eco-SOD; GPX; P22Phox; PPARGC1; PPARα*Retrospective, single group, longitudinal. VO~2peak~ tested pre & post intervention.*N* = 935 coronary artery disease patients (CAD); 76 females; Caucasian; age 56 ± 0.3 yrs.; BMI 25.8 ± 0.1 kg/m^2^; 5% smokers; 85% cardiac medications; 5% diabetes; 27% hypertension.Peripheral blood leucocytesInvader TM Assay (third wave technologies)CARAGENE: 3 mths; supervised; 3×/week; 90 mins; \~ intensity = 80% (HR/peakHRx100)Silva, 2011, Brazil*NOS3*Single group, longitudinal. VO~2peak~ tested pre & post intervention.*N* = 80 Portuguese police recruits; 20--35 years; BMI 23.3 ± 3.6 kg/m^2^; no health concerns; inactive.Peripheral blood leucocytesPCR-RFLP18 weeks; supervised; 3×/week/ 80 mins; intensity graded to VT HR.Timmons, 2010, UK*GWAS*1: Single group, longitudinal. VO~2max~ & muscle biopsies tested pre & post intervention; 2: Blind test. VO~2max~ & muscle biopsies tested pre & post intervention; 3: Retrospective: HERITAGE WHITES data1: N = 24 sedentary healthy Caucasian men (23 ± 1 yrs., 1.82 ± 0.02 m, 78.6 ± 2.7 kg); 2: 17 active & healthy Caucasian men (29 ± 6 yrs., 81.8 ± 9 kg, 1.8 ± 0.5 m); 3: HERITAGE Caucasians (as described in Bouchard 2011).Lymphoblastoid cell lines from venous bloodIllumina Human CNV370-Quad Bead Chips1: 6 weeks; supervised MICT; 4 × 45 min cycling sessions/week @ 70% VO~2max~.\
2:12 weeks; cycle ergometer 5×/week. Peak power test performed every Mon to determine intensity for week: Tues: 3 min intervals at 85%. P~max~ separated by 3 min intervals at 40% P~max~; Thurs: 8 min intervals at 85% P~max~ separated by 3 min intervals at 40% P~max~; Fri: 120 min at 55% P~max~ continuously; duration increased by 5%/wk.; last 6 wks duration maintained but intensity increased by 1%/week; 3: HERITAGE WHITES Study (as described in Bouchard 2011).Jenkins, 2010, USA*PLIN haplotypes*Retrospective, single group, longitudinal. VO~2max~ tested; body composition; pre & post intervention; dietary stabilisation (American Heart Association).N = 46 M & 55 F Caucasians (50--75 years); inactive; no major health concerns; BP \< 160/99; non-smokers; BMI \< 37 kg/m^2^; no meds for BP, cholesterol or glucose control; at least one lipid abnormality.UnknownTaqMan allelic discrimination assay using qPCR24 weeks; supervised; multi-modal MICT; progressive; 3×/wk.; 20--40 min; up to 70% VO~2max~ reached; 60 min walk home included post 12 wks.Alves, 2009, Brazil*ACE & Angiotensin*Single group, longitudinal. VO~2max~ and echocardiography of left ventricle pre and post intervention.*N* = 83 Brazilian policemen; age 26 years ±4.5; BMI 24 kg/m^2^ ± 1; healthy; normotensive.UnknownPolymerase chain reaction protocol.17 weeks; supervised MICT; 50--80%VO~2peak~; 60 min × 3/week.He, 2008a, China*NRF-1*Single group, longitudinal; VO~2max~, VT and RE tested pre & post intervention.*N* = 102 Chinese male soldiers; no health concerns; age 18.8 ± 0.9 yrs.; wt 60.3 ± 6.5 kg; ht. 1.71 ± 5.8 m; no medications; non-smokers.Peripheral blood leucocytesPCR-RFLP assay18 wks; supervised; 3×5000m running sessions/wk.; 95%--105% VT.He, 2008b, China*PPARGC1*Single group, longitudinal; VO~2max~, VT and RE tested pre & post intervention.N = 102 Chinese male soldiers; no health concerns; age 18.8 ± 0.9 yrs.; wt 60.3 ± 6.5 kg; ht. 1.71 ± 5.8 m; no medications; non-smokers.Peripheral blood leucocytesPCR-RFLP assay18 wks; supervised; 3×5000m running sessions/wk.; 95%--105% VT.He, 2007a, China*TFAM*Single group, longitudinal. VO~2max,~ VT and RE tested pre & post intervention.N = 102 Chinese male soldiers; no health concerns; age 18.8 ± 0.9 yrs.; wt 60.3 ± 6.5 kg; ht. 1.71 ± 5.8 m; no medications; non-smokers.Peripheral blood leucocytesPCR-RFLP assay18 wks; supervised; 3×5000m running sessions/wk.; 95%--105% VT.He, 2007b, China*NRF-2/NFE2L2*Single group, longitudinal. VO~2max~, VT and RE tested pre & post intervention.N = 102 Chinese male soldiers; no health concerns; age 18.8 ± 0.9 yrs.; wt 60.3 ± 6.5 kg; ht. 1.71 ± 5.8 m; no medications; non-smokers.Peripheral blood leucocytesPCR-RFLP assay18 wks; supervised; 3×5000m running sessions/wk.; 95%--105% VT.Hautala, 2007, USA*PPARD*Retrospective, single group, longitudinal. VO~2max~, body composition and lipids tested pre & post intervention.*N* = 477 from HERITAGE Caucasian study (183 female)\
*N* = 264 from HERITAGE African-American study (247 female)UnknownSNP scorer genotyping software20 wks; supervised; progressive, MICT; 3×/wk.; 55--75% VO~2max~; 30--50 min.Defoor, 2006a, Belgium*ADRB1*Retrospective, single group, longitudinal. VO~2peak~ tested pre & post intervention.N = 935 coronary artery disease patients (CAD); 76 females; Caucasian; age 56 ± 0.3 yrs.; BMI 25.8 ± 0.1 kg/m^2^; 5% smokers; 85% cardiac medications; 5% diabetes; 27% hypertension.Peripheral blood leucocytesInvader assayCARAGENE: 3 mths; supervised; 2-3×/wk.; 80% HR~max~; 90 mins/session.Defoor, 2006b, Belgium*ACE*Retrospective, single group, longitudinal. VO~2peak~ tested pre & post intervention.*N* = 935 coronary artery disease patients (CAD); 76 females; Caucasian; age 56 ± 0.3 yrs.; BMI 25.8 ± 0.1 kg/m^2^; 5% smokers; 85% cardiac medications; 5% diabetes; 27% hypertension.Peripheral blood leucocytesInvader assayCARAGENE: 3 mths; supervised; 2-3×/wk.; 80% HR~max~; 90 mins/session.He, 2006, China*HBB*Retrospective, single group, longitudinal. VO~2max,~ VT and RE tested pre & post intervention.N = 102 Chinese male soldiers; no health concerns; age 18.8 ± 0.9 yrs.; wt 60.3 ± 6.5 kg; ht. 1.71 ± 5.8 m; no medications; non-smokersPeripheral blood leucocytesPCR-RFLP assay18 wks; supervised; 3x5000m running sessions/wk.; 95%--105% VTDefoor, 2005*CKMM*Retrospective, single group, longitudinal. VO~2peak~ tested pre & post intervention.N = 935 coronary artery disease patients (CAD); 76 females; Caucasian; age 56 yrs. ± 0.3; BMI 25.8 kg/m^2^ ± 0.1; 5% smokers; 85% cardiac medications; 5% diabetes; 27% hypertension.Peripheral blood leucocytesInvader assayCARAGENE: 3 mths; supervised; 2-3×/wk.; 80% HR~max~; 90 mins/session.Leon, 2004, USA*APOE*Retrospective, single group, longitudinal. VO~2max~, blood lipids tested pre & post intervention; counselled not to alter health habits.*N* = 241 male and 89 female HERTIAGE Caucasians; 17--65 years; inactive; no major health concernsLymphoblastoid cell lines from venous bloodPCR-RFLP assayHERTIAGE: 20 wks; supervised; progressive MICT; 3×/wk.; 55--75% VO~2max~; 30--50 min.Thompson, 2004, USA*APOE*Single group, longitudinal. VO~2max~, anthropometric data and lipid levels collected pre & post intervention; dietary control.*N* = 170 Caucasians (120 completed program -- 60 M and F); 18--70 years (39 ± 11 years); consumed less than 2 drinks/day; physically inactive; BMI \<31; no major health concerns.Peripheral blood leucocytesPCR-RFLP assay6 months supervised progressive training; 60--80% of VO~2max~; increasing from 15 to 40 mins during first 4 wks. Once at 40 mins, maintained this for 4 sessions each week for 5--6 months. Multimodal but treadmill primary aerobic activity.Rico-Sanz, 2003, Canada*AMPD1*Retrospective, single group, longitudinal. VO~2max~, submax and submax to maximal tested pre & post intervention.*N* = 329 HERTAGE Caucasians and 90 HERITGAE African-Americans measured for training response; 17--65 years; inactive; no major health concerns.UnknownPCR protocol + separation on agarose gelsHERITAGE: 20 wks; supervised; progressive MICT; 3×/wk.; 55--75% VO~2max~; 30--50 minPrior, 2003, USA*HIF1A*Single group, longitudinal. VO~2max~ tested pre & post intervention.*N* = 101 Caucasian and 22 African-Americans in good health; age 57.7 ± 0.91 yrs.; BMI 29.2 ± 0.64 kg/m^2^Peripheral blood lymphocytesPCR-RFLP assay24 weeks; supervised; progressive MICT; 3×/wk.; 20--40 min; 50--70% VO~2max~Woods, 2002, UK*ACE*Single group, longitudinal. VO~2max,~ and HR/VO~2~ relationship tested pre & post intervention.*N* = 59 Caucasians with ACE II allele and 29 without ACE DD allele; \~age 18.9 yrs.; \~ht. 1.78 m; \~ wt 73.4 kg; military camp.Peripheral blood leucocytesPCR protocol + polyacrylamide gel separation11 weeks; supervised aerobic training; 75% squads; 35% adventurous training; 25% running and circuit training.Murakami, 2001, Japan*MtDNA*Single group, longitudinal. VO~2max~ tested pre & post intervention*N* = 41 Japanese M (age 20.6 ± 2.2 yrs), inactive; no major health concerns; wt 62.8 ± 7.5 kg; ht. 171.8 ± 6.7 cm.Peripheral blood leucocytesPCR-RFLP assay8 weeks; supervised 1×/week out of 3.5; 60 min/session; 70% VO~2max~Sonna, 2001, USA*ACE*Double-blind study. VO~2peak,~ anthropometrics physical fitness assessment for active duty personnel tested pre and post intervention.*N* = 85 F and 62 M; age 21.7 ± 3.6 yrs.; 84 Caucasian, 20 Hispanic, 1 Native Americans, 5 Asian and 37 African-American; no major health concerns; BMI 23.1 ± 3.1 kg/m^2^; BF% 27.9 ± 6.1 F and 16.4 ± 5.7 M.Peripheral blood leucocytesPCR-RFLP assay8 weeks supervised; 6 days/week; 2 x aerobic (sprints & 3--5 miles) & 2 x strength. Participants place in 1 of 4 ability groups so all running for same duration. Participants also completed road marches and other drills.Rankinen, 2000a, USA*Na + −K + ATPaseα*Retrospective, single group, longitudinal. VO~2max~ and max power output tested pre & post intervention.HERITAGE WHITES: 472 Caucasians; 17--65 years; inactive; no major health concerns.Lympohblastoid cell linesPCR protocol + agarose gel separationHERTIAGE: 20 wks; supervised; progressive MICT; 3×/wk.; 55--75% VO~2max~; 30--50 minRankinen,2000b, USA*ACE*Retrospective, single group, longitudinal. V0~2max~, VE, VT, blood lactate, oxygen, stroke volume, carbon dioxide, HR, tested pre & post intervention (submax VO~2~ test for older patients).HERITAGE WHITES AND BLACKS: 476 Caucasian & 248 Blacks; 17--65 years; inactive; no major health concerns.Lympohblastoid cell linesPCR protocol + agarose gel separationHERTIAGE: 20 wks; supervised; progressive MICT; 3×/wk.; 55--75% VO~2max~; 30--50 minHagberg, USA, 1999*APOE*Retrospective, single group, longitudinal. VO~2max~ and lipid levels tested pre and post; stabilised on American Heart Association diet 8 weeks prior to intervention.*N* = 51; 40--80-year-old sedentary men (61 ± 3 yrs); overweight with \~BF% 30 ± 3; BP \< 160/95 mmHg; no major health concerns or medications for blood lipids or glucose.Peripheral blood leucocytesPCR-RFLP assay9 months' endurance training; multimodal; 5--7 months supervised and last 2--4 months used heart rate monitor to ensure 70--80% VO~2max~ intensity and 3 days/week for 45 min was complied with.Rivera, 1999, Canada*CKMM*Retrospective, single group, longitudinal. VO~2max~ tested pre & post intervention.HERITAGE WHITES: 495 Caucasians from 98 families; 17--65 years; inactive; no major health concerns.Lympohblastoid cell linesPCR-RFLP assayHERTIAGE: 20 wks; supervised; progressive MICT; 3×/wk.; 55--75% VO~2max~; 30--50 minRivera, 1997, Canada*CKMM*Retrospective, single group, longitudinal. VO~2max~ tested pre & post intervention.HERITAGE WHITES: 160 Caucasian parents and 80 offspring; 17--65 years; inactive; no major health concerns.Lympohblastoid cell linesPCR-RFLP assayHERTIAGE: 20 wks; supervised; progressive MICT; 3×/wk.; 55--75% VO~2max~; 30--50 minDionne, 1991, Canada*mtDNA*Single group, longitudinal. VO~2max~ tested pre & post intervention.N = 46 M from Quebec (17--27 yrs) & 27 M from Tempe (24--29 yrs); inactivePeripheral blood leucocytesPCR-RFLP assayQuebec: 20 weeks; supervised; progressive training; Max 85% HRR; max 45 min/session; 3×/wk.\
Tempe: 12 weeks; supervised; progressive training; max 70--77% VO~2max~; max 40 min/session; 3×/wkBouchard, 1989, Canada*AK1M*\
*CKM*RCT. VO2max, total power output tested pre & post intervention.*N* = 295 M 7 F (18--30 years); healthy CaucasiansMuscle biopsy and peripheral blood leucocytesFormazan technique?Group 1: 15 weeks; supervised; progressive MICT; 30--45 min/session; 3-5×/wk.; 60--85% HRR\
Group 2: 15 weeks; supervised; progressive interval training; 1-2×/week; 80--85% HRR separated by 5 min recovery.*M* male, *F* female, *wks* weeks, *mths* months, *wt* weight, *ht.* height, *yrs.* years, *BMI* body mas index, *BF %* body fat percentage, *VO* ~*2max*~ maximal oxygen uptake/cardiorespiratory fitness, *PCR* polymerase chain reaction protocol, *RFLP* restriction fragment length polymorphism, *qPCR* Quantatitive Polymerase Chain Reaction, *RCT* randomised controlled trial, *GWAS* genome wide association study, *HRT* hormone replacement therapy, *SNP* single nucleotide polymorphism, *AT* anaerobic threshold, *MICT* moderate intensity interval training, *HR* heart rate, *HRR* heart rate reserve, *HR* ~*max*~ heart rate maximum, *P* ~*max*~ maximal aerobic power, *Submax* submaximal, *Cal/kcal* calories, *mtDNA* mitochondrial DNA, *BP* blood pressure

A summary of key findings from the included articles is provided in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Limitations were assessed by two authors (CW and JC) based on the intervention, genotyping method used, study design and sample used. Table [4](#Tab4){ref-type="table"} was developed to highlight which predictor genes for VO~2max~ trainability merited further exploration. A third author (MW) examined Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} to ensure all genetic variants, genomic coordinates and genotypes, were described with a consistent annotation.Table 2Summary of findings from candidate gene studiesGeneVariantChromosomeAuthor & DateRaceAgeSexHealth concerns(+/−/0)\* Genotype & VO~2max~ training responseP-value (x)Highest training intensitySessions/weekDuration per session (min)Training periodTraining modality*PPARGC1*Intron 7G/C22Onkelinx, 2011935 Caucasian\~56M&FY (CAD)GG, CG, CC (0)0.5180% HRmax2--3903 monthsAmbulatoryHe, 2008b102 Chinese\~19MNAll variants (0)\> 0.0595--105% VT3Time to finish.18 weeks5000 m running*APOE*E2: rs7412 (c.526C \> T; p.Arg176Cys)\
E3: WT\
E4: rs429358 (c.388 T \> C; p.Cys130Arg)\
E3/E3: WT/WT\
E2/E3: p.Arg176Cys/WT\
E4/E3: p.Cys130Arg/WT\
E2/E2: p.Arg176Cys/p.Arg176Cys\
E2/E4: p.Arg176Cys/p.Cys130Arg\
E4/E4: p.Cys130Arg/p.Cys130Arg19Yu, 2014360 Chinese18--40M\
F\
M\
F\
M&FNE2/E3 in M (+) n = 20\
E2/E3 F (+) n = 25\
E3/E4 M (+) n = 31\
E3/E4 F (+) n = 29\
E2/E2; E2/E4; E3/E3; E4/E4 in M&F (0)0.04\
0.03\
0.02\
0.02\
\> 0.0560--85% VO~2max~'Progressive' but details NA'Progressive' but details NA6 monthsTreadmillLeon, 2004265 Caucasian17--65M&FNAll variants (0)\> 0.0575% VO~2max~330--5020 weeksCycle ergoThompson, 2004170 Unknown\~39M&FNE3/E3 (−) n = 43\
E2/E3 (0) n = 40\
E3/E4 (0) n = 41\< 0.0160--85% VO~2max~4Up to 50 min6 monthsTreadmill*CKM*1170 & 985 + 18519Defoor, 2005935 Caucasian\~56M&FY (CAD)AA; GG; A/G (0)\> 0.0580% HRmax2--3903 monthsAmbulatoryRivera, 1999240 Caucasian17--65M&FNCKM locus (*n* = 227)\< 0.0175% VO~2max~330--5020 weeksCycle ergoRivera, 1997495 Caucasian17--65M&FNHomozygotes 1170bpa allele (−) *n* = 12\< 0.0575% VO~2max~330--5020 weeksCycle ergoBouchard, 1989295 Caucasian18--30M&FNAll variants (0)\> 0.051. 60--85% HRR\
2: 80--85% HRR1: 1--2\
2: 3--51: Intervals\
2: 30--451: 15\
2: 151: Cycling\
2: Cycling*ACE*Insertion (I) or Deletion (D)17Alves, 200983 Brazilian\~26MNAll variants (0)\> 0.0550--80% VO~2peak~2--360 min17 weeksRunningRankinen, 2000b476 Caucasian\
248 AA17--65M&FNDD Caucasian offspring (+)\
*n* = 810.04275% VO~2max~330--5020 weeksErgo cycleDefoor, 2006935 Caucasian\~56M&FY (CAD)II (+) (frequency of 0.3 M and 0.36 F)Entire group: 0.047\
No Ace inhibitors: 0.01380% HRmax2--3903 monthsAmbulatoryWoods, 200259 Caucasian\~19MNII; I/D; DD (0)\>0.22NANANA11 weeksSquads, adventure training, running, circuitsSonna, 2001147 Caucasian, 37 AA, 26 other19--24M&FNII, DD (0)\>0.05NA4--690 min8 weeksMilitary training*CYBA; P22Phox*A24G -- 640A \> G16Onkelinx, 2011935 Caucasian\~56M&FY (CAD)AA, AG, GG (0)\
CC, CT, TT (0)0.78\
0.9480% HRmax2--3903 monthsAmbulatory*PLIN*PLIN1 (6209 T \> C) -- rs2289487\
15:g.90217096C \> T\
PLIN4 (11482G \> A) -- rs894160\
15:g.90211823C \> T\
PLIN5 (13041A \> G -- rs2304795\
15:g.90210263A \> G\
PLIN6 (149954A \> T -- rs1052700\
15:g.90208310A \> T15Jenkins, 2010101 CaucasianNAM&FNGenotypes and haplotypes (0)*p* \> 0.05Up to 70% VO~2max~320--40 min24 weeksMulti-modal*AKT*rs1130214 (4:g.105259734C \> A)14McKenzie, 2011109 Caucasian50--75M\
FElevated BP, cholesterol, menopauseAll genotypes sig. Increased, but GT/TT men (+) *n* = 220.03750--70%HRR320--40 min24 weeksMulti-modal*HIF1A*T + 140C (rs11549465)\
A-2500 TCh 14Prior, 2003101 Caucasian\
22 AA\>60\
\<60M&FNCT & TT in Caucasian over 60 (−) *n* = 37\
All other ages, race and genotypes (0)0.03\
\>0.05\
\>0.0550--70% VO~2max~320--40 min24 weeks'Aerobic training'*Na + −K + −ATPase α2*Alpha2 exon 1\
Alpha2 exon 21--2213Rankinen, 2000a472 Caucasian17--65M&FN3.3/3.3 (−) *n* = 5\
10.5/10.5 offspring (+) *n* = 140.018\
0.01755--75% VO~2max~330--5020 weeksCycle ergo*HBB*-551C/T -- no rs ID\
11:g.5248801 T \> C\
+16, intron 2 - rs10768683\
11:g.5247791C \> G\
+340 -- no rs ID\
11:g.5246488 T \> A11He, 2006102 Chinese\~19MNCC, CT, TT (0)\
CC, CG, GG (0)\
AA, AT, TT (0)\>0.0595--105% VT3Time to finish.18 weeks5000 m running*CNTF*rs1800169 (11:g.58391501G \> A)11Thomaes, 2011935 Caucasian\~56M&FNAA (+) *n* = 210.00280% HR max2--3903 monthsAmbulatory*CAT*-262C \> T11Onkelinx, 2011935 Caucasian\~56M&FY (CAD)TT (−) *n* = 3420.0280% HR max2--3903 monthsAmbulatory*GSTP1*rs1695 (11:g67352689A \> G\
c.313A \> G p.Ile105Val)11Zabreska, 201466 Polish19--24FNGG & AG (+) *n* = 30Absolute: 0.029\
Relative: 0.02550--75% HR max3603 months'Aerobic routine'*ADRB1*Pos. 145\
Pos. 116510Defoor, 2006935 Caucasian\~56M&FY(CAD)Ser49Gly49, Ser49Ser49,80% HR max2--3903 monthsAmbulatoryGly49Gly49 (0)\
GLy389Gly389,0.18Gly389Arg389, Arg389Arg389 (0)0.75*TFAM*rs1937 (10:g.60145342G \> C\
c.35G \> C p.Ser12Thr)\
rs2306604 (10:g.60148692A \> G)\
rs1049432 (10:g.60155120G \> T)10He, 2007b102 Chinese\~19MNGG, CG, CC (0)\
AA, AG, GG (0)\
GG, GT, TT (0)\>0.0595--105% VT3Time to finish.18 weeks5000 m running*NOS3*T-1495A -- No rs ID\
7:g.150689397A \> T\
A-949G -- rs1800779\
7:g.150689943G \> A\
-786 T \> C-- rs41322052\
7:g150690106C \> T\
G298A -- rs1799983\
7:g.150696111 T \> G\
c.894 T \> G (p.Asp298Glu))7Onkelinx, 2011935 Caucasian\~56M&FY (CAD)TT, TA, AA (0)\
AA, AG, GG (0)\
TT, TC, CC (0)\
TT, CT, C (0)\
CC, CT, TT (0)\
GG, GA, AA (0)0.54\
0.76\
0.69\
0.69\
1.88\
1.0480% HRmax2--3903 monthsAmbulatory-786 T \> C-- rs41322052\
7:g150690106C \> T\
Intron 4 -- rs61722009\
VNTR (repeat)\
7:g.150694276_150694302AGGGGTG\
894G \> T -- rs1799983\
7:g.150696111 T \> G\
c.894 T \> G (p.Asp298Glu))7Silva, 201180 Portuguese20--35MNTT, CC, TC (0)\
4b4b, 4ba4c, 4a4a (0)\
GG, GT, TT (0)\
*\*All genotypes sig. Increased. fitness, thus no difference between groups*0.001Graded to VT HR380 min18 weeksRunning*NRF-1*C&T - rs2402970\
7:g.80647382G \> T\
A & G - rs10500120\
7:g.129393341A \> G\
rs6949152\
7:g129286436A \> G7He, 2008a102 Chinese\~19MNCC, CT, TT (0)\
AA, AG, GG (0)\
AA, AG, GG (0)0.38\
0.110\
0.09495--105% VT3Time to finish.18 weeks5000 m running*AK1M*common and rare variants7Bouchard, 1989295 Caucasian18--30M&FN(0)\> 0.051. 85% HRR\
2: 85% HRR1: 1--2\
2: 3--51: Intervals\
2: 30--451: 15\
2: 151: Cycling\
2: Cycling*PPARD*Exon 4 + 15\
Exon 7 + 65Ch 6Hautala, 2007Caucasian AA17--65M&FNCC genotype in AA of Exon 4 + 15 (−) *n* = 190.00575% VO~2max~330--5020 weeksCycle ergo*VEGF*405\
4606Onkelinx, 2011935 Caucasian\~56M&FY (CAD)GG, GC, CC (0)\
CC, CT, TT (0)0.52\
0.5280% HR max2--3903 monthsAmbulatory*GR/NR3C1*rs6190 (5:g.142780337C \> T\
c.68G \> A p.Arg23Lys)5Thomaes, 2011935 Caucasian\~56M&FY (CAD)G/A (+) *n* = 55\<0.0180% HR max2--3903 monthsAmbulatory*PPARα*Gly482Ser4Onkelinx, 2011935 Caucasian\~56M&FY (CAD)GG, G, SS (0)0.59\
0.880% HR max2--3903 monthsAmbulatory*SOD3*C760G4Onkelinx, 2011935 Caucasian\~56M&FY (CAD)CC (0)\
G carrier (0)0.12\
0.1880% HR max2--3903 monthsAmbulatory*GPX*197P \> L3Onkelinx, 2011935 Caucasian\~56M&FY(CAD)Pro197Pro (0)\
Leu-carrier (0)0.18\
0.7880% HR max2--3903 monthsAmbulatory*NFE2L2*Rs125949\
Rs8031031\
Rs7181862He, 2007b102 Chinese\~19MNCC, CA, AA (0)\
CT, TT, AA (0)\
AG, GG (0)\> 0.0595--105% VT3Time to finish.18 weeks5000 m running*AMPD1*AMPD1:c.133C (rs17602729)1Thomaes, 2011935 Caucasian\~56M&FNCC (+) *n* = 652\< 0.0580% HR max2--3903 monthsAmbulatoryRico-Sanz, 2003329 Caucasian\
90 AA17--65M&FNTT (−) in Caucasians (*n* = 6)\< 0.00675% VO~2max~330--5020 weeksCycling*mtDNA*MTND5\
m.13470A \> C or A \> G\
m.12406G \> A\
m.13365C \> TmtDNA SNP via restriction enzymeMurakami, 200121 Japanese20.6MNAll variants (0)\> 0.0570% VO~2max~3--460 min8 weeksErgo Cycle*mtDNA*Within mitochondriaDionne, 199153 Quebec, Tempe17--27MNmtDNA subunit 5 N5 (−) *n* = 30.05Quebec: 85% HRR\
Tempe:77% VO~2max~Quebec: 3\
Tempe: 3--5Quebec:45 min\
Tempe:40 minQuebec: 20 wks\
Tempe: 12 wksErgo Cycle*ALAS2*≤166 bpMitochondriaXu, 201572 Chinese18--22MN≤166 bp (+) *n* = 25\< 0.05'High/Low training'330 min4 weeksErgo Cyclewhere possible, gene variants were annotated using the references sequence (GRCh37/hg19)*CAD* coronary artery disease, *wks* weeks, *mths* months, *VO* ~*2max*~ maximal oxygen uptake/cardiorespiratory fitness, *AT* anaerobic threshold, *HRR* heart rate reserve, *HRmax* heart rate maximum, *Pmax* maximal aerobic power, *Cauc* Caucasian, *AA* African-American, *M* male, *F* female\*\*(+) = high training response, (−) = low training response, (0) = neutral training response(x) = p-value has been adjusted for covariates except for article by Xu et al. (2015) where it wasn't clear if p-value had been adjusted (ALAS~2~) Table 3Summary of hypothesis-free studiesGeneVariantChromosomeMapPositionMinor allele frequency (MAF) frequencyRaceGenderAgeTraining periodSessions/wkSession durationSessions intensity(+/−/0)\*\* genotype/expression and VO2max response to trainingP-valueAuthor, Date*\^\*CAMTA1 intronicrs88473616,937,6920.411. 473 Caucasian*\
*2. 259 African-AmericanM&F*\
*M&F17--65*\
*17--6520 wks3×/wk30--50 min55--75% VO* ~*2*~ *maxAA (−)1. 1.49* × *10-* ^4^\
*2. 0.03*\
*3. 1.54 × 10* ^*−4*^*Bouchard, 2011 (1&2)*\
*Ghosh, 2013 (3)*+ID3rs11574 (1:g.23559007 T \> C c.313A \> G p. Thr105Ala)123,758,085NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA2.1 × 10^−3^Timmons, 2010*\*RGS18*\
*5′ upstream of gene (non-coding)rs10921078 (1:g.192059022G \> A)1190,325,6450.151. 483 Caucasian*\
*2. 259 African-AmericanM&F17--6520 wks3×/wk30--50 min55--75% VO* ~*2*~ *maxGG (−) n = 5671. 7.17* × *10\~* ^5^\
*2. 0.032Bouchard, 2011***\^RYR2**\
**intronicrs7531957 (1:g.237789656 T \> G)1235,856,2790.08473 Caucasian)M&F17--6520 wks3×/wk30--50 min55--75% VO** ~**2**~ **maxNA1:6.42** × **10--** ^**5**^\
**2:1.18 × 10** ^**−4**^**Bouchard, 2011 (1)**\
**Ghosh, 2013 (2)\#SCLC45A1NA1NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO** ~**2**~ **maxNA\#89.1Ghosh, 2013**MAST2rs2236560146,268,021NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010SYPL2rs120493301109,832,711NA41 CaucasianMYoung adults1.6 wks\
2.12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010\#ACVR1CNA2NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#85.8Ghosh, 2013SLC4A5rs828902274,323,642NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNANATimmons, 2010KCNF1/NLGN1rs2003298 (2:g.11086150 T \> C)211,003,6010.42473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.21 × 10\~^4^Bouchard, 2011\* FLJ44450rs4952535 (2:g.42131523G \> A)241,985,0270.41473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxG (+)1.01 × 10-^4^Bouchard, 2011++TTNrs10497520 (2:g.179644855 T \> C c3601A \> G p.Lys1201Glu)2175,353,1000.50473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA2.5 × 10^−3^Timmons, 2010++NRP2\
intronicrs3770991 (2:g.206655739A \> G)2206,363,984NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.4 × 10^−3^Timmons, 2010CREB1rs27093562208,120,337NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNANATimmons, 2010SCN3Ars75749182165,647,425NA473 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010\^HCG22rs2517512 (6:g.31029685C \> T)6NA0.18473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA3.09 × 10^−5^Ghosh, 2013\*KCNH8 (268 kb)rs4973706 (3:g.18921772 T \> C)318,896,7760.24473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxA (+)5.31 × 10\~^5^Bouchard, 2011*\*ZIC4 (146 kb) intronicrs117158293148,439,8560.081. 473 Caucasian*\
*2. 183 CaucasianM&F*\
*M&F17--65*\
*40--6520 wks*\
*6 mths3×/wk.*\
*3-4×/wk30--50 min*\
*4-8 kcal/kg/week55--75% VO* ~*2*~ *max*\
*+50%VO* ~*2*~ *maxAA (−) n = 48.68* × *10-* ^6^\
*0.032Bouchard, 2011*\*NLGN1 (110 kb)\
intronicrs2030398 (3:g.173005973G \> A)3174,488,6670.20473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxA (+)1.32 × 10\~^4^Bouchard, 2011\^ADCYNA3NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#86.1Ghosh, 2013AMOTL2rs133222693135,569,834NA41 CaucasianMYoung adults1.6 wks\
2.12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010CSN1S2B\
intronicrs2272040 (4:g71007047A \> G)471,041,6360.13473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA5.05 × 10-^5^Bouchard, 2011\*LOC100289626 (134 kb)rs2053896 (4:g137154796G \> A)4137,374,2460.10473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxA (+)6.62 × 10\~^5^Bouchard, 2011**\^\*ACSL1rs6552828 (4:g.185725416A \> G)4185,962,4100.37473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO** ~**2**~ **maxAA (−)1:1.31** × **10--** ^**6**^\
**2:3.8 × 10** ^**−6**^**Bouchard, 2011 (1)**\
**Ghosh, 2013 (2)**\^SLED1rs65528284NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA3.8 × 10^−6^Ghosh, 2013\^C4orf40rs3775758 (4:g.71008910C \> T)4NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.09 × 10^−4^Ghosh, 2013\^TECrs13117386 (4:g.48252763G \> C)4NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA7.97 × 10^−5^Ghosh, 2013\#NLNNA5NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#88Ghosh, 2013FAABP6rs77346835NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.44 × 10^−4^Ghosh, 2013TTC1rs21768305159,380,7140.13473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.42 × 10\~^4^Bouchard, 2011BTNL9rs8889495180,425,011NA41 CaucasianMYoung adults1.6 wks\
2.12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010RTN4IP1/QRSL1rs8988966107,169,855NA41 CaucasianMYoung adults1.6 wks\
2.12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010HCG22rs2523849631,133,0300.17473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA7.53 × 10-^5^Bouchard, 2011HCG22rs2523848631,133,0830.17473 CaucasianM & F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA7.53 × 10\~^5^Bouchard, 2011HCG22rs2428514631,135,4950.15473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA8.22 × 10-^5^Bouchard, 2011HCG22rs2517518631,136,3240.17473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA7.53 × 10\~^5^Bouchard, 2011HCG22rs2523840631,138,4040.17473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA7.53 × 10-^5^Bouchard, 2011HCG22rs2517506631,139,6590.17473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA7.53 × 10\~^5^Bouchard, 2011\*PRDM1 (287 kb)rs104990436106,353,8300.13473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxA (+)3.93 × 10-^6^Bouchard, 2011\*ENPP3 (17 kb)rs104526216132,127,0940.12473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxA (+)1.23 × 10\~^4^Bouchard, 2011+SLC22A3rs24575716160,754,818NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxDownregulated in high responders3.0 × 10^−3^Timmons, 2010\^TMEM181NA6NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#84.5Ghosh, 2013\^PARK2NA6NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#84.8Ghosh, 2013\^SNX14NA6NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#86.7Ghosh, 2013\^BTBD9NA6NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#86Ghosh, 2013\^KCNQ5NA6NANA473 Caucasian1.M&F\
2. M1.17--65\
2. young adults1.20 wks\
2. 6--12 wks1. 3×/wk.\
2. 3--4/wk1. 30--50 min\
2. 45 min vs progressive1. 55--75% VO~2~max\
2. 70% vs progressiveNA\
NA1:\#85.9\
2:NAGhosh, 2013 (1), Timmons, 2010 (2)PPARDrs2076167635,499,765NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNANATimmons, 2010HDAC9rs3814991718,601,4280.11473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.46 × 10-^4^Bouchard, 2011WBSCR17 (35 kb)rs12538806770,200,7770.30473 CaucasianM & F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.47 × 10\~^4^Bouchard, 2011WBSCR17 (33 kb)rs13235325770,202,9430.30473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.47 × 10-^4^Bouchard, 2011++CPVLrs4257918729,020,374NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxUpregulated in high responders3.1 × 10^−3^Timmons, 2010\^ITGB8rs102651497NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA7.04 × 10^−5^Timmons, 2010LHFPL3NA7NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA84.34Ghosh, 2013PILRBrs13228694799,778,243NA41 CaucasianYoung adults17--651.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010+DEPDC6rs73861398121,096,600NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.85×10^−2^Timmons, 2010**\#PINX1N/A8NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO** ~**2**~ **maxNA88.2Ghosh, 2013**\*GRIN3A (516 kb)rs15356289104,056,5700.09473 CaucasianM & F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA6.81 × 10\~^6^Bouchard, 2011GRIN3A (540 kb)rs9590669104,081,0840.27473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.35 × 10-^4^Bouchard, 2011\*C9orf27 (33 kb)rs121154549117,759,8710.11473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxG (+)7.74 × 10\~^5^Bouchard, 2011\^TTLL11rs70221039NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.08 × 10^−4^Ghosh, 2013KCNT1N/A9NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#86.5Ghosh, 2013KLF4rs46315279109,309,857NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010TET1rs124134101070,055,236NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010PRKG1N/A10NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#87.3Ghosh, 2013\^+SVILrs64816191030,022,960NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.0 × 10^−3^Timmons, 2010+BTAF1rs27920221093.730,409NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.2 × 10^−2^Timmons, 2010CASC2rs141318410NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.65 × 10^−4^Ghosh, 2013KIF5Brs8068191032,403,990NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNANATimmons, 2010+H19rs22551375111,976,072NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxUpregulated in high responders4.0 × 10^−4^Timmons, 2010ACTN3rs18157391066,084,671NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNANATimmons, 2010BTAF1rs27920221093,730,409NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010\*LOC100130460rs21980091110,360,1530.50473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxA (+)2.28 × 10-^5^Bouchard, 2011\*DBX1 (64 kb)rs105008721120,202,2990.15473 CaucasianM & F17--6520 wks3×/wk30--50 min55--75% VO~2~maxA (+)6.49 × 10\~^6^Bouchard, 2011**\^\*CD44rs3536251135,125,1220.32473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO** ~**2**~ **maxNA1:1.12** × **10--** ^**4**^\
**2:1.64 × 10** ^**−4**^**Bouchard, 2011 (1)**\
**Ghosh, 2013 (2)**CXCR5 (36 kb)rs493856111118,223,6950.23473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA9.29 × 10\~^5^Bouchard, 2011\* CXCR5 (24 kb/) BLR1rs793300711118,235,8790.23473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA7.35 × 10-^5^Bouchard, 2011\^CD6rs17509811NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.11 × 10^−4^Ghosh, 2013**\^SHANK2rs1075130811NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO** ~**2**~ **maxNA8.11 × 10** ^**−5**^**Ghosh, 2013\#GRIK4N/A11NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO** ~**2**~ **maxNA88.32Ghosh, 2013**H19rs2251375111,976,076NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010FAM19A2rs216845212NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.34 × 10^−4^Ghosh, 2013\^C12orf36 (14 kb)rs125804761213,435,3300.14473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.08 × 10\~^4^\
2. 1.45 × 10^−4^Bouchard, 2011 (1)\
Ghosh, 2013 (2)**\^NALCNN/A13NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO** ~**2**~ **maxNA\#85Ghosh, 2013**+MIPEPrs73245571323,194,862NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA5.1 × 10^−3^Timmons, 2010\^EEF1DP3rs277396813NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA3.67 × 10^−6^Ghosh, 2013\^CLYBLN/A13NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#85.4Ghosh, 2013\*TTC6rs128967901437,343,6730.09473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA3.59 × 10-^5^Bouchard, 2011METTL3rs12638091421,058,740NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010TTC6rs80188891437,353,3420.09473 CaucasianM & F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA5.25 × 10\~^5^Bouchard, 2011*\*DAAM1rs1956197 (14:g.59477414C \> T)1458,547,1670.161. 473 Caucasian*\
*2. 464 Caucasian1.M*\
*2. F17--65*\
*Post menopause20 wks*\
*6 mths3×/wk.*\
*120-170 min/wk30--50 min*\
*120--170 min/wk55--75% VO* ~*2*~ *max*\
*+50%VO* ~*2*~ *maxAA (−) n = 841.43* × *10-* ^5^*Bouchard, 2011\*NDN (75 kb)*\
*Downstream of NDNrs8242051521,559,1640.151. 473 Caucasian*\
*2. 464 Caucasian1.M*\
*2.F17--65*\
*Post menopause20 wks*\
*9 mths3×/wk.*\
*120-170 min/wk30--50 min*\
*120-170 m in/wk55--75% VO* ~*2*~ *max*\
*40--85%VO* ~*2*~ *maxGG (−) n = 5213.45* × *10\~* ^5^\
*0.05Bouchard, 2011*+DIS3Lrs15465701564,382,829NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA2.3 × 10^−2^Timmons, 2010UNKLrs3751894161,426,876NA473 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010IL32rs13335163,052,198NA473 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010**\#RPTORN/A17NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO** ~**2**~ **maxNA\#89Ghosh, 2013**\#VPS53N/A17NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#84Ghosh, 2013ACEDI1758,919,622NA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNANATimmons, 2010SMTNL2rs7217556174,425,585NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010ZSWIM7R211715,825,286NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010ENOSF1rs378635518671,962NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010EMR4rs7256163196,909,1340.31473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.13 × 10-^4^Bouchard, 2011IER2rs8920201913,8185NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010DNAJB1rs49262221914,488,050NA41 CaucasianMYoung adults1.6 wks\
2. 12 wks1. 4×/wk.\
2. 3×/wk1. 45 min\
2. Progressive1. 70% VO~2~max\
2. ProgressiveNANATimmons, 2010g.63226200G \> Ars60903142061,327,9970.16473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxA (+)1:6.48 × 10\~^5^\
2:6.24 × 10^−5^Bouchard, 2011 (1)\
Ghosh, 2013 (2)\^YTHDF1rs612240320NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA6.24 × 10^−5^Ghosh, 2013**\^MACROD2N/A20NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO** ~**2**~ **maxNA\#86.6Ghosh, 2013**\^HLS21N/A21NANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA\#84.7Ghosh, 2013\*MN1 (14 kb)rs7383532226,460,0720.35473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxA (+)1.23 × 10--^4^Bouchard, 2011LOC731789rs11015207NANANA473 CaucasianM&F17--6520 wks3×/wk30--50 min55--75% VO~2~maxNA1.61 × 10^−4^Ghosh, 2013There were no other possible mediators (such as medications, health concerns) or other significant findings noted in the above three studies. Where possible, gene variants were annotated using the references sequence (GRCh37/hg19)\*Out of the 39 SNPs identified via GWAS, 21 (\*) explained 49% of the VO~2~ max trainability variance (after regression analysis). The 15 most significant were then examined using data from the following studies: HERITAGE African-Americans, DREW study, STRRIDE study. The variants replicated are in italics+11 SNPs from a regression analysis explained \~23% of the estimated VO~2~ max variance. 90% RNA expression remained unchanged by exercise training. (++) were found in study by Bouchard (2011) but weren't included in the regression analysis because they weren't considered significant at the 0.00015 level\^Top 20 GWAS associated genes based on second-best SNP-*P* values\#Candidate genes identified through CANDID software based on literature search; GWAS association data; sequence conversion & gene expression. This equates to a 'final score' rather than p-value. Bolded text indicates moderate-strong related biological mechanisms that influence VO~2~ max trainability\*\*(+) = significantly higher training response(0) = no significant difference in training response between genotypes(−) = significantly lower training response Table 4Predictor genes that may influence VO~2max~ training responseNumberChromosomeGeneVariantRaceGenotype/expression and VO~2max~ training response (+/−/0)\*\*Author, Date (x = candidate gene study)1**1*AMPD1*rs17602729CaucasianTT and CT (−)Thomaes, 2011 (x); Rico-Sanz, 2003 (x)**21***CAMTA1*rs884736Caucasian**\
**African-AmericanAA (−)Bouchard, 2011; Ghosh, 2013**31*ID3*rs11574CaucasianTBCTimmons, 2010**41*RGS18*rs10921078Caucasian**\
**African-AmericanGG (−)Bouchard, 201151*RYR2*rs7531957CaucasianTBCBouchard, 2011; Ghosh, 2013**61*SLC45A1*TBCCaucasianTBCGhosh, 201372*ACVR1C*TBCCaucasianTBCGhosh, 201382*KCNF1*rs2003298CaucasianTBCBouchard, 201192*FLJ44450*rs4952535CaucasianG (+)Bouchard, 2011102*TTN*rs10497520CaucasianTBCTimmons, 2010112*NRP2*rs3770991CaucasianTBCTimmons, 2010123*KCNH8*rs4973706CaucasianA (+)Bouchard, 2011**133*ZIC4*rs11715829CaucasianAA (−)Bouchard, 2011**143*NLGN1*rs2030398CaucasianA (+)Bouchard, 2011153*ADCY5*TBCCaucasianTBCGhosh, 2013164*CSN1S2B*rs2272040CaucasianTBCBouchard, 2011174*LOC100289626*rs2053896CaucasianA (+)Bouchard, 2011**184*ACSL1*rs6552828CaucasianAA (−)Bouchard, 2011; Ghosh, 2013**194*SLED1*rs6552828CaucasianTBCGhosh, 2013204*PRR27; C4orf40*rs3775758CaucasianTBCGhosh, 2013214*TEC*rs13117386CaucasianTBCGhosh, 2013225*NR3C1*rs6190CaucasianGG (−)Thomaes, 2011235*NLN*TBCCaucasianTBCGhosh, 2013245*FABP6*rs7734683CaucasianTBCGhosh, 2013255*TTC1*rs2176830CaucasianTBCBouchard, 2011266*PPARD*Exon 4 + 15\
Exon 7 + 65African-AmericanCC (−)Hautala, 2007 (x)276*HCG22*rs2517512CaucasianTBCGhosh, 2013286*HCG22*rs2523849CaucasianTBCBouchard, 2011296*HCG22*rs2523848CaucasianTBCBouchard, 2011306*HCG22*rs2428514CaucasianTBCBouchard, 2011316*HCG22*rs2517518CaucasianTBCBouchard, 2011326*HCG22*rs2523840CaucasianTBCBouchard, 2011336*HCG22*rs2517506CaucasianTBCBouchard, 2011346*PRDM1*rs10499043CaucasianA (+)Bouchard, 2011356*ENPP3*rs10452621CaucasianA (+)Bouchard, 2011366*SLC22A3*rs2457571CaucasianDownregulated in high respondersTimmons, 2010376*TMEM181*TBCCaucasianTBCGhosh, 2013386*PARK2*TBCCaucasianTBCGhosh, 2013396*SNX14*TBCCaucasianTBCGhosh, 2013406*BTBD9*TBCCaucasianTBCGhosh, 2013416*KCNQ5*TBCCaucasianTBCGhosh, 2013427*HDAC9*rs3814991CaucasianTBCBouchard, 2011437*WBSCR17*rs12538806CaucasianTBCBouchard, 2011447*WBSCR17*rs13235325CaucasianTBCBouchard, 2011457*CPVL*rs4257918CaucasianTBCTimmons, 2010467*ITGB8*rs10265149CaucasianTBCGhosh, 2013477*LHFPL3*TBCCaucasianTBCGhosh, 2013488*DEPDC6*rs7386139CaucasianTBCTimmons, 2010498*PINX1*TBCCaucasianTBCGhosh, 2013509*GRIN3A*rs1535628CaucasianTBCBouchard, 2011519*GRIN3A*rs959066CaucasianTBCBouchard, 2011529*C9orf27*rs12115454CaucasianG (+)Bouchard, 2011539*TTLL11*rs7022103CaucasianTBCGhosh, 2013549*KCNT1*TBCCaucasianTBCGhosh, 20135510*FAM238B; LOC731789*rs11015207CaucasianTBCGhosh, 20135610*PRKG1*TBCCaucasianTBCGhosh, 20135710*SVIL*rs6481619CaucasianTBCTimmons, 20105810*BTAF1*rs2792022CaucasianTBCTimmons, 20105910*CASC2*rs1413184CaucasianTBCGhosh, 20136011*H19*rs22551375CaucasianUpregulated in high respondersTimmons, 20106111*LOC100130460*rs2198009CaucasianA (+)Bouchard, 20116211*DBX1*rs10500872CaucasianA (+)Bouchard, 2011**6311*CD44*rs353625CaucasianTBCBouchard, 2011; Ghosh, 2013**6411*CXCR5 (36 kb)*rs4938561CaucasianTBCBouchard, 20116511*CXCR5 (24 kb)/BLR1*rs7933007CaucasianTBCBouchard, 20116611*CD6*rs175098CaucasianTBCGhosh, 20136711*SHANK2*rs10751308CaucasianTBCGhosh, 20136811*GRIK4*TBCCaucasianTBCGhosh, 20136911*CNTF*rs1800169CaucasianAA (+)Thomaes, 2011 (x)7011*CAT*-262C \> TCaucasianTT (−)Onkelinx, 2011 (x)7111*GSTP1*c.313A \> G (rs1695)CaucasianGG & AG (+)Zarebska, 2014 (x)7212*FAM19A2*rs2168452CaucasianTBCGhosh, 20137312*C12orf36*rs12580476CaucasianTBCBouchard, 2011\
Ghosh, 20137413*NALCN*TBCCaucasianTBCGhosh, 20137513*MIPEP*rs7324557CaucasianTBCTimmons, 20107613*EEF1DP3*rs2773968CaucasianTBCGhosh, 20137713*CLYBL*NACaucasianTBCGhosh, 20137813*Na + −K + −ATPase α2*Alpha2 exon 1\
Alpha2 exon 21--22Caucasian3.3/3.3 (−)\
10.5/10.5 (+)Rankinen, 2000a (x)7914*HIF1A*T + 140CCaucasian (60+ years)C/T (−)Prior, 2003 (x)8014*AKT1*G205 T (RS1130214)Caucasian menGT & TT (+)McKenzie, 2011 (x)8114*TTC6*rs12896790CaucasianC (+)Bouchard, 2011**8214*DAAM1*rs1956197CaucasianAA (−)Bouchard, 20118315*NDN*rs824205CaucasianGG (−)Bouchard, 2011**8415*DIS3L*Rs1546570CaucasianTBCTimmons, 2010**8517*ACE*Intron 16CaucasianDD (+)**\
**II (+)Rankinen, 2000b (x); Defoor, 2006 (x)**8617*RPTOR*NACaucasianTBCGhosh, 20138717*VPS53*NACaucasianTBCGhosh, 20138819*ADGRE3P; EMR4*rs7256163CaucasianTBCBouchard, 2011**8919*APOE*TBCChinese & unknownE2/E3 (+)**\
**E2/E3 (+)**\
**E3/E4 (+)**\
**E3/E4 (+)**\
**E3/E3 (−)Yu, 2014 (x); Thompson, 2004 (x)9019*CKM*NcolCaucasianHomozygous 1170 bp (−); CKM locus (+/−)Rivera, 1999(x); Rivera 1997 (x)9120*BIRC7 and YTHDF1*rs6090314CaucasianA (+)Bouchard, 2011**\
**Ghosh, 2013**9220*YTHDF1*rs6122403CaucasianTBCGhosh, 20139320*MACROD2*NACaucasianTBCGhosh, 20139421*HLCS*NACaucasianTBCGhosh, 20139522*MN1*rs738353CaucasianA (+)Bouchard, 201196Mitochondria*ALAS2*\</=166 bpChinese\</=166 bp (+)Xu, 2015 (x)97Mitochondria*mtDNA*TBCQuebec, TempemtDNA subunit 5 N5 (−)Dionne, 1991 (x)Where possible, gene variants were annotated using the references sequence (GRCh37/hg19)Bolded = genes that have been replicated between or within studies**\*\***(+) = high training response, (−) = low training response, (0) = neutral training response, *TBC* to be confirmed whether variant contributes to a high or low training response

Results {#Sec3}
=======

Of the 1635 articles identified, 35 met the inclusion criteria (see Fig. [1](#Fig1){ref-type="fig"}). A summary of these articles is provided in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. From the 35 articles, 97 genetic variants were identified as being significantly associated with VO~2max~ trainability (Table [4](#Tab4){ref-type="table"}).Fig. 1PRISMA flow chart of article selection process

Study characteristics {#Sec4}
---------------------

Across the studies DNA samples from 4212 individuals were used. Tissue sources were predominantly blood leucocytes, lymphoblastoid cell lines and buccal cells. Genotype was primarily identified through PCR-RFLP (polymerase chain reaction restriction fragment length polymorphism based analysis) for candidate genes and Illumina Human CV370-Quad Bead Chips for GWAS analysis (which can capture over 370,000 SNPs per participant).

Overall, 68% of participants in the reviewed studies were men, and ages ranged from 17 to 75 years. The average BMI of participants was 25.3 kg/m^2^ (SD 2.36)~.~ Where detailed, DNA samples were taken from a variety of ethnicities, including Caucasian (74.5%), Asian (13.5%), African-American (7.5%), Hispanic (4.3%) and Native American (0.2%).

The 35 included articles described 15 cohorts, with three cohorts providing subject data for 19 articles (see Table [1](#Tab1){ref-type="table"} for details). Nine articles \[[@CR20]--[@CR28]\] used data from the HERITAGE study and five \[[@CR29]--[@CR33]\] reviewed Caucasian participant data from the Cardiac Rehabilitation and Genetics of Exercise Performance and Training Effect (CARAGENE) study. Five studies examined clinical data from 102 young male and apparently healthy police recruits in China \[[@CR34]--[@CR38]\]. The remaining samples came from independent clinical studies focusing on apparently healthy but sedentary adults from a variety of ethnicities including Caucasians, Asians, African-Americans, Native American and Hispanics \[[@CR13], [@CR39]--[@CR53]\].

Most reviewed studies (*n* = 32) used a single-group longitudinal design. However, one study compared three groups using a longitudinal design \[[@CR28]\]. One study used retrospective data from two Randomized Controlled Trials (RCT) \[[@CR20]\]; and one was a double-blind study \[[@CR39]\].

Twenty-eight studies examined a MICT intervention. Two studies examined protocols using High Intensity Interval Training (HIIT) \[[@CR28], [@CR40]\]. The 5 remaining studies trained participants by running at Ventilatory Threshold (VT) \[[@CR34]--[@CR38]\]. Training intensity was measured using a percentage of VO~2max~, Heart Rate Reserve (HRR), VT, Maximal Power (P~max~) or Maximum Heart Rate (HR~max~). Intensities varied between 50 and 85% VO~2max~, 95% -105% VT, 50--85% P~max~, 80--85% HRR and 50--80% HR~max~. Training volume varied between 20 to 90 min per session (2-4×/week). The period of interventions ranged from 4 weeks to 9 months. Training modalities consisted primarily of cycle ergometers and treadmills.

Only six studies incorporated a standardized diet prior to and during the intervention period \[[@CR23], [@CR41]--[@CR45]\]. Three articles included strength training \[[@CR20], [@CR39], [@CR47]\] and two studies included military training \[[@CR39], [@CR47]\] as the intervention.

Genotyping findings {#Sec5}
-------------------

Candidate gene studies

The candidate gene association approach requires a prior hypothesis that the genetic polymorphisms of interest are causal variants or in strong linkage disequilibrium (LD) with a causal variant, and would be associated with a particular exercise-related phenotype at a significantly different rate than predicted by chance alone (may be higher or lower). This approach is effective in detecting genetic variants that are either directly causative, or belong to a shared haplotype that is causative \[[@CR54]\]. Thirty-two candidate gene studies were based on the gene's molecular function and possible association with VO~2max~ trainability (Table [2](#Tab2){ref-type="table"}).

### Genes associated with muscular subsystems {#Sec6}

VO~2peak~ can be influenced by muscle efficiency and it has been hypothesized that genes encoding muscular subsystems may contribute to the genetic variability in VO~2peak~ training response \[[@CR33]\]. Twelve genes and 21 genetic variants related to muscular phenotypes were investigated in 935 (76 female) cardiac patients from the CARAGENE study \[[@CR33]\]. Three out of the 21 genetic variants were significantly associated (*p* \< 0.05) with an increase in VO~2peak~ following 3 months of MICT (2--3 × 90-min sessions per week at 80% HR~max~; *p* \< 0.05). These variants included *GR*:c.68 \> A (G/A genotype, number of people with genotype; *n* = 55) in the glucocorticoid receptor gene (*GR*; rs6190), *CNTF*:c.115-6G \> A (AA genotype, *n* = 21) in the ciliary neurotrophic factor gene (*CNTF*; rs1800169) and the *AMPD1*:c.133C wild type (CC genotype, *n* = 652) of the adenosine monophosphate deaminase gene (*AMPD1*; rs17602729). Furthermore, a larger change in relative VO~2peak~ was reported in patients with a greater number of these variants described (Area Under the Curve (AUC): 0.63; 95% Confidence Interval (CI): 0.56--0.7; *p* \< 0.01). More specifically, those with a gene predictor score (GPS) of one or less positive response alleles had an average increase in VO~2peak~ of 16.7%. Those with four or more positive response alleles had an average increase of 25%, with each positive response allele contributing approximately 1% (13.5 mL/min) to the increase in VO~2peak~.

Caucasians aged between 17 and 65 years from the HERITAGE study who were homozygous (TT genotype) for the *AMPD1*:c.133C \> T (p.(Gln45\*)) (rs17602729) variant (*n* = 6), had a lower VO~2max~ training response (\<121 mL/min; *p* = 0.006), compared to the CT and CC genotypes (*n* = 497) following 20 weeks of MICT (3 × 50 min per week at 55--75% HR~max~) \[[@CR46]\].

The serine/threonine protein kinase 1 (*AKT1*) gene has been linked to growth and skeletal muscle differentiation \[[@CR44]\]. In a study of 109 Caucasians (50--75 years old), men (*n* = 22) with the *AKT1*:c.-350G \> T (rs1130214) variant (TT/GT genotype) significantly increased their VO~2max~ compared to men (*n* = 29) with the GG genotype (fold increase of 1.2 ± 0.02 vs 1.1 ± 0.02, *p* = 0.037) following 24 weeks of MICT (3 × 20--40 min per week at 50--75% HRR) \[[@CR44]\].

The glutathione S-transferase P1 (*GSTP1*) c.313A \> G variant has been associated with an impaired ability to remove excess reactive oxygen species. This is hypothesised to increase the exercise training response by better activation of cell signalling pathways resulting in positive muscle adaptations \[[@CR45]\]. While investigating 62 Polish females' (19--24 years-old) response to 12 weeks of MICT (3 × 60 min per week at 50--75% HR~max~), participants (*n* = 30) with the *GSTP1*:c.313A \> G (GG + GA genotype) demonstrated a 2 mL/kg/min greater improvement in VO~2max~ compared to AA genotypes (*n* = 5) following training (absolute *p* = 0.029, relative *p* = 0.026, effect size = 0.06) \[[@CR45]\].

### Genes associated with electrolyte balance {#Sec7}

The electrogenic transmembrane ATPase (*NA+/K + −ATPase*) gene may contribute to VO~2max~ trainability by affecting the electrolyte balance and membrane excitability in working muscles \[[@CR24]\]. Examining Caucasian data from the HERITAGE study, it was found that those homozygous for a recurrent 3.3-kb deletion in the exon 1 of the *ATP1A2* gene (*n* = 5) had a 41% (45 mL/min) lower training response compared to heterozygotes (*n* = 87) \[[@CR24]\]. This exon encodes on part (alpha-2-subunit) of the *Na+/K + ATPase* protein. This genotype also had a 48% (197 mL/min) lower VO~2max~ training response than homozygotes (*n* = 380) for a repeated 8.8-kb in the exon 1 of the *ATP1A2* gene following 20 weeks of MICT (*p* = 0.018) \[[@CR24]\]. VO~2max~ gains were 29% (130 mL/min) and 39% (160 mL/min) greater in offspring homozygous for a 10.5-kb deletion in exon 21--22 (*n* = 14) compared to heterozygotes (*n* = 93) and homozygotes (*n* = 187) respectively (*p* = 0.017) \[[@CR24]\].

The angiotensin-converting enzyme (*ACE*) gene contributes to blood pressure, fluid and salt balance \[[@CR55]\]. Elite endurance athletes are more likely to have the Insertion (I) allele \[[@CR56]\] which relates to lower *ACE* activity and reduced blood pressure response during exercise, whereas sprint/power athletes are more likely to have the Deletion (D) allele and the DD genotype \[[@CR57]\] and subsequently higher *ACE* activity. Caucasians from the CARAGENE study with the homozygous II genotype (frequency of 0.23 and 0.18 for men and women respectively) had a 2.1% greater VO~2max~ training response (*p* = 0.047) compared to the DD genotype (frequency of 0.3 and 0.36 for men and women respectively) \[[@CR31]\]. When eliminating those on *ACE* inhibitors, the improvement increased by 3% (*p* = 0.013) \[[@CR31]\]. On the other hand, VO~2max~ trainability was 14--38% greater (*p* = 0.042) in HERITAGE Caucasian offspring with the DD genotype (*n* = 81) \[[@CR25]\]. Three studies found no association with *ACE* or angiotensinogen genetic variants and VO~2max~ training response in 53 Caucasians (average age 19 years) following 12 weeks of military training \[[@CR47]\]; 147 multi-ethnic 19--24 year-old adults following 8 weeks of military training \[[@CR39]\]; and 83 Brazilian policemen (average age 26 years) following 17 weeks of MICT (3 × 60 min per week at 50--85% VO~2peak~) \[[@CR48]\].

### Genes associated with lipid metabolism {#Sec8}

Genotypes of the perilipin (*PLIN1*) gene may influence training response via intracellular lipolysis and energy production \[[@CR43]\]. In 101 Caucasians (50--75 years old), there were no significant differences between carriers and non-carriers of the *PLIN1*:c.504 T \> A variant (rs1052700) after 24 weeks of MICT (20--40 min, 3 × per week) \[[@CR43]\].

The peroxisome proliferator activated receptor delta (*PPARD*) gene affects fatty acid oxidation and energy production \[[@CR22]\]. African-Americans (*n* = 19) from the HERITAGE study with the *PPARD* exon 4 + 15 (CC genotype) had a significantly lower VO~2max~ training response (\> 50 mL/min lower; *p* = 0.028) and power output (\> 15 W lower; *p* = 0.005) compared to the C/T and TT genotypes (*n* = 230) \[[@CR22]\].

Apolipoprotein E (*APOE*) variants affect the level of lipids in the blood, cell lipid uptake and endothelial vascular dilation \[[@CR23]\]. *APOE* has 3 common alleles: E2 (TT/TT), E3 (TT/CC), E4 (CC/CC) at two SNPs (rs429358, rs7412), which can create six possible genotypes (E2/E2, E3/E3, E4/E4, E2/E3, E2/E4, E3/E4) \[[@CR58]\]. The *APOE* E4 allele has been associated with Alzheimer's disease \[[@CR59]\], higher levels of low density cholesterol (LDL-C) and a greater risk of coronary heart disease compared to E3 (wild-type) and E2 carriers \[[@CR23]\]. Chinese men (18--40 years) with the *APOE* E2/E3 (*n* = 20) and E3/E4 (*n* = 31) genotypes had a significantly higher VO~2max~ training response (Odds Ratio (OR) = 0.68 (95% CI (0.04, 1.32); *p* = 0.04 and OR = 0.60 (95% CI (0.09, 1.11); *p* = 0.02 respectively) compared to other *APOE* genotypes following 6 months of progressive MICT (3 x per week at 60--85% VO~2~max) \[[@CR13]\]. Similarly, Chinese women (18--40 years) with the *APOE* E2/E3 (*n* = 25) and E3/E4 (*n* = 29) genotypes had significantly higher VO~2max~ training responses compared to other *APOE* genotypes (OR = 0.62 (95% CI = 0.05, 1.18); *p* = 0.03 and OR = 0.62(95% CI = 0.09,1.15); *p* = 0.02 respectively) \[[@CR13]\]. Men and women (ethnicity unknown) with the E3/E3 *APOE* genotype (*n* = 43) had an 8% lower training response compared to the E2/E3 (*n* = 40) and E3/E4 genotypes (*n* = 37) (*p* \< 0.01, Bonferroni-corrected) following 6 months of MICT (4 × 50 min per week at 60--85% VO~2max~) \[[@CR42]\]. However, there was no significant difference in the VO~2max~ training response between *APOE* genotypes in men and women from the HERITAGE study (*n* = 766) \[[@CR23]\]. Similarly, in 51 males (40--80 years old, ethnicity not confirmed) there was no difference in VO~2max~ training response between genotypes \[[@CR41]\].

### Genes associated with oxidative phosphorylation and energy production {#Sec9}

Mitochondrial DNA (*mtDNA*) encodes several enzyme subunits involved in oxidative phosphorylation, and may be a key factor in endurance and cardiorespiratory fitness \[[@CR56]\]. Research of *mtDNA* variants in 41 inactive Japanese men (mean age 20.6) failed to find a significant difference in trainability after 8 weeks of MICT (3--4 × 60 min per week at 70% VO~2max~) \[[@CR49]\]. On the contrary, 3 men (17--25 years) with the *mtDNA* variant in subunit 5 of ND5 had a lower VO~2max~ training response compared to other mtDNA variants (\~ gain 0.22 L/min less, *p* \< 0.05) following 12-weeks of MICT (3--5 × 45 min per week at 85%HRR~max~) \[[@CR50]\].

The creatine kinase muscle (*CKM*) gene has been associated with reduced fatigue from increased adenosine triphosphate (ADP) production \[[@CR26], [@CR27]\]. Using data from the HERITAGE study, parents and offspring homozygote for the 1170 bp allele (*n* = 12) had a lower VO~2max~ training response (3 times and 1.5 times lower respectively; *p* \< 0.05) compared to other *CKM* genotypes (*n* = 148). This explained 9 and 10% of the inter-individual variation in VO~2max~ change respectively \[[@CR26]\]. A nominal genetic linkage was identified in siblings (*n* = 277) who shared two alleles (1170 base pairs or 985 + 185 base pairs) at the *CKM* locus identical by descent (IBD), with these siblings having similar changes in VO~2max~ compared to siblings with fewer alleles IBD (*p* = 0.04) \[[@CR27]\]. In an earlier study focusing on muscle specific inherited variations, no association was found in 295 Caucasians (18--30 years old) between *CKM* or adenylate kinase (*AK1*) variants after a randomized control trial that included 15 weeks of endurance training versus maximal power contraction interval training \[[@CR40]\]. Similarly, no association was found with the *CKM* gene and VO~2max~ trainability in 937 Caucasian patients with coronary artery disease following 3 months of MICT (2--3 × 90 min aerobic sessions per week at 80% HR~max~) \[[@CR29]\].

Nuclear respiratory factor 1 *(NRF1*) and nuclear factor (erythroid-derived 2)-like 2 (*NFE2L2*) \[[@CR36], [@CR37]\], contribute to mitochondrial biogenesis and oxidative phosphorylation \[[@CR60]\]. In a study involving 102 physically active Chinese male soldiers (average age 19 years), there was no association between *NRF1* and *NFE2L2* genotypes or haplotypes and VO~2max~ trainability after 18 weeks of 3 × 5000 m runs per week at 95--105% VT \[[@CR36], [@CR37]\].

### Genes associated with oxygen delivery {#Sec10}

Nitric oxide causes coronary and arterial vasodilation, contributing to oxygen delivery regulation \[[@CR32]\]. Data from the CARAGENE study was used to investigate genes associated with nitric oxide bioavailability \[[@CR32]\]. These included nitric oxide synthase 3 (*NOS3*), cytochrome b-245 alpha chain (*CYBA*, also known as *p22-PHOX*), glutathione peroxidase (*GPX1*), catalase (*CAT*), superoxide dismutase 3 (*SOD3*), vascular endothelial growth factor A (*VEGFA*), peroxisome proliferator-activated receptor alpha (*PPARα*) and peroxisome proliferator-activated receptor gamma coactivator-related 1 (*PPARC1*) \[[@CR32]\]. Participants carrying the C allele of the *CAT*:c.262 T \> C variant (*n* = 342) had up to 3.1% greater improvements in VO~2max~ training response compared to participants with the TT genotype (*n* = 521) following MICT (*f* = 3.6; *p* = 0.02). Participants with the *NOS3* 1.4 haplotype combinations (*n* = 36) had a 6.4% lower training response compared to the 3.3. haplotype combinations (*n* = 133) (*p* \< 0.05). However, these associations were not significant after Bonferroni correction. No other associations were found with other genes or haplotypes related to nitric oxide availability and endothelial function \[[@CR32]\]. Similarly, in a cohort of 80 Portuguese (20--35 years old) police recruits, there was no association between *NOS3* genotypes (−786 TT/TC/CC, 894 GT/TT/GG) and VO~2peak~ response following 18 weeks of 3 × 80-min per week of graded running training \[[@CR59]\]. Additionally, no association was found with *PPARGC1* and VO~2max~ trainability in 102 Chinese male polices recruits following MICT \[[@CR36]\].

The beta-2-adrenergic receptor (*ADBR2*) gene helps to support oxygen delivery to working muscles via the adrenergic receptors \[[@CR30]\]. In participants from the CARAGENE study, there was no association found between *ADBR2* genotypes or haplotypes, and VO~2max~ trainability \[[@CR30]\].

The hypoxia-inducible factor 1 alpha (HIF1A) gene is a transcriptional regulator that controls angiogenesis (blood vessel development) and metabolism by increasing the expression of hypoxia-induced genes, such as *VEGF* \[[@CR52]\]. Caucasians 60 years and over with the *H1F1A*:c.1744C \> T (rs11549465; C/T genotype; *n* = 37) had a significantly lower training response (0.3 mL/kg/min; *p* = 0.03) compared to those with the CC genotype (*n* = 64) following 24 weeks of MICT (3 × 20--40 min per week at 50--70% VO~2max~) \[[@CR52]\].

The 5′-aminolevulinate synthase 2 (*ALAS2*) gene is highly expressed in erythroid cells and is imperative for hemoglobin and myoglobin synthesis \[[@CR53]\]. Seventy-two Chinese participants (18--22 years old) allocated to one of 13 *ALAS2* genotypes with compound dinucleotide repeats lengths (157 bp −184 bp), were placed in a 4-week 'HiHiLo' training program (varying between low and high altitude training at 75% VO~2max~) \[[@CR53]\]. Baseline hemoglobin levels and change in VO~2max~ with training was significantly higher in subjects (*n* = 25) with the dinucleotide repeats ≤ 166 bp (*p* \< 0.05). No significant associations were found between VO~2max~ trainability and other genes related to oxygen transport and utilization genotypes in 102 young Chinese soldiers following 18 weeks of 3 × 5000 m runs per week \[[@CR35], [@CR37], [@CR38]\]. These genes include mitochondrial transcription factor A (*TFAM*) \[[@CR35]\] and hemoglobin-beta locus (*HBB*) \[[@CR38]\].2.Hypotheses free studies

Over the last decade, with the advent of technological advances allowing researchers to genotype millions of genetic variants (e.g. SNPs) in each individual, the investigation of the contribution of common variants to traits is now feasible. Unbiased and hypothesis-free genome wide association studies (GWAS) for exercise/health-related traits have emerged.

Three studies have used GWAS to identify genes associated with the VO~2max~ response to exercise training \[20, 21 28\]. These are outlined in Table [3](#Tab3){ref-type="table"}.

The first investigated two clinical trials and data from the HERITAGE study \[[@CR28]\]. RNA expression profiling and VO~2max~ testing was performed on 24 healthy and inactive Caucasian men (average age 24 years) before and after a 6-week training intervention (4 × 45-min cycling sessions per week at 70% VO~2max~). Muscle biopsies from the vastus lateralis were collected and the RNA expression of genes was correlated with changes in VO~2max~ by analysing oligonucleotide arrays. Pearson correlations were used to identify the relationships between the median logit normalised probe sets and the number of times they were selected. In the 24 subjects, using a median correlation cut-off greater than 0.3, 29 genes were selected greater than 22 out of 24 times. The sum of expression of these 29 genes were found to have a significant linear relationship with VO~2max~ change following endurance training (*r* ^2^ = 0.58, *p* \< 0.00001). Across the group, VO~2max~ changes improved on average by 14% and ranged from −2.8% to 27.5% (*p* = 0.0001). More than 20% of the group had a response less than 5%. A gene set enrichment analysis found that the oxidative phosphorylation gene was upregulated (False Discovery Rate (FDR) = 1.1%), which was associated with an increased reliance on lipids during training (RER decreased on average by 10% post training, *p* \< 0.0001). To identify if these predictor genes would be similar in a different sample, a 12-week blind study on 17 young and active Caucasian men was conducted. Training consisted of 1-day of testing, 2 sessions of interval training (3 × 3-min intervals at 40--85% P~max~) and 2 × 60--120-min cycle sessions (55--60% P~max~) each week. The 29 predictor genes were also significantly associated with VO~2max~ trainability in this group (*p* = 0.02). The haplotypes of these predictor genes were then genotyped using candidate genes identified from the HERITAGE study. Six genetic variants were associated with VO~2max~ trainability: *SMTNL2, DEPDC6, SLC22A3, METTL3, ID3* and *BTNL9* (*p* \< 0.01 each). A stepwise regression model using 25 variants from the predictor set and 10 variants from the HERTIAGE study (Table [3](#Tab3){ref-type="table"}) found that eleven SNPs (included in Table [4](#Tab4){ref-type="table"}) contributed to 23% of the differences seen in residual VO~2\ max~ gains, which correlated to approximately 50% of the genetic variability in VO~2max~ trainability (seven variants from the RNA predictor set and four from the HERITAGE project). Reciprocal RNA expression validation found that three of four HERITAGE candidate genes enhanced the original RNA transcript predictor model. Overall, more than 90% of gene expression did not change. However, *OCT3* was downregulated in high responders and *H19* was upregulated in low responders (FDR \<5%). *BTNL9, KLF4* and *SMTNL2* also had small but inconsistent changes in expression (i.e. dissimilar in high vs low responders) (FDR \< 5%).

A GWAS examining 324,611 variants from the HERITAGE study was completed to identify possible predictor genes associated with VO~2peak~ \[[@CR20]\]. Based on single-variant analysis, 39 variants (Table [3](#Tab3){ref-type="table"}) were associated with gains in VO~2peak~ although none of these achieved genome-wide or suggestive significance (*p* = 1.5 × 10^−4^) \[[@CR19]\]. The strongest predictor for training response was found in the Acyl-CoA synthetase long-chain family member 1 (*ACSL1*) gene (4:g.185725416A \> G; rs6552828) which accounted for 7% of the training response (*p* = 1.31 × 10^−6^). After a stepwise multiple regression analysis of the thirty-nine variants, 21 were suggested to account for (or at least contribute to) 49% of the variance in VO~2max~ trainability (included in Table [4](#Tab4){ref-type="table"}; *p* \< 0.05). The strongest predictors were found in SNPs associated with: PR domain-containing protein 1 (*PRDM1*); glutamate receptor, ionotropic, N-methyl-D-aspartate 3A (*GRIN3A*); N-methyl-D-aspartate receptor (*NMDA*); potassium voltage-gated channel subfamily H member 8 (*KCNH8*); zinc finger protein of cerebellum 4 (*ZIC4*); and, *ACSL1*. An unweighted 'predictor score' based on contribution to VO~2max~ of these 21 variants was created. A score of '0' represented homozygote for the low-response variant; '1' represented heterozygous and '2' represented homozygous for the high-response allele. Individuals with a score equal to or less than 9 (*n* = 36) had an average VO~2max~ score improvement of 221 mL O~2~/min. Alternatively, those (*n* = 52) with a score equal to or greater than 19 had an average VO~2max~ increase of 604 mL/min.

The 15 most significant variants were tested for replication in a sample of African-Americans from the HERITAGE study, women in the Dose Response to Exercise (DREW) study (*n* = 112), and the men and women in the Study of a Targeted Risk Reduction Intervention through Defined Exercises (STRRIDE) (*n* = 183) \[[@CR20]\]. Variants in the *NDN* (15:g.24008071 T \> C; rs824205) and *DAAM1* (14:g.59477414C \> T; rs1956197) were replicated in the DREW study, the *Z1C4* (3:g.146957166 T \> C T; rs11715829) variant was replicated in the STRRIDE study and *CAMTA1* (7:g.7015105 T \> C; rs884736) and *RGS18* (1:g.192059022G \> A; rs10921078) variants were replicated in African-Americans from the HERITAGE study. Four variants in the genes supervillin (*SVIL*), neuropillin 2 *(NRP2*), titin (*TTN*) and carbozypeptidase (*CPVL*) identified by Timmons et al. \[[@CR28]\] were also found by Bouchard et al. \[[@CR20]\], however, at a significance of 0.008, these variants were not included in the multi-variate regression analysis.

Using the HERITAGE cohort, an extended analysis was performed, with 2.5 million variants analysed \[[@CR21]\]. To reduce bias associated with outlier variants, the second most significant variant *p*-value was used to determine genotype and changes in VO~2max~. Even with an extended analysis, the *ACSL1* gene was shown to have the most significant variant (4:g.185725416A \> G; rs6552828), which confirmed findings by Bouchard et al. \[[@CR20]\], whom identified the most significant variant at each gene (Table [3](#Tab3){ref-type="table"}). The following genes and their variants were also replicated in both studies: *CAMTA1* (rs884736), *RYR2* (rs7531957), g.63226200G \> A (rs6090314), *C12orf36* (rs12580476) and *CD44* (rs353625) \[[@CR20], [@CR21]\].

The gene prioritisation tool 'CANDID' was then used to rank candidate genes for changes in VO~2max~ \[[@CR21]\]. This was done via: 1) a weighted analysis based on variant gene expression in targeted tissues; 2) GWAS p-value change in VO~2max~; 3) literature related to candidate genes; and 4) 'cross species sequence conservation' \[[@CR21]\]. The top-ranking candidate genes from the GWAS and CANDID tool (Table [1](#Tab1){ref-type="table"}) were then investigated for possible biological mechanisms and changes in VO~2max~. As a result, variants were allocated into four groups: 1) broad effects on exercise-related processes (such as the electron transport chain, physical fitness, skeletal development and other cardiorespiratory markers); 2) moderately strong scores against selective exercise-related processes; 3) high and low scores across several exercise-related processes; 4) low scores across all exercise-related processes.

Variants and their involvement in pathways related to changes in VO~2max~ response were then examined \[[@CR21]\]. Out of the sixteen pathways found, variants related to pantothenate and co-enzyme A (CoA) biosynthesis, *PPAR* gene signalling and immune function signalling had the highest level of 'burden' (variants contributing to trainability). The variants related to long-chain fatty acid transport (including *ACSL1*) and fatty acid oxidation strongly influence VO~2max~ training response via lipid metabolism process and the tricarboxylic acid cycle, both of which affect the availability of adenosine triphosphate and subsequently training response.

Predictor genes {#Sec11}
---------------

Out of the 35 articles analysed (candidate genes and GWAS studies), 97 predictor genes were identified as possible contributors to VO~2max~ trainability (Table [4](#Tab4){ref-type="table"}). These genes were based on what authors deemed significant, or the most significant, for their particular study. Thirteen of these predictor genes were replicated between at least two studies (bolded in Table [4](#Tab4){ref-type="table"}). The traits for VO~2max~ trainability (e.g. which genotype was related to the training effect and whether it was a low or high responding genotype) was not outlined for each variant and hence this will require confirmation in future studies.

Discussion {#Sec12}
==========

This systematic review aimed to summarize genetic variants that have been identified as influencing VO~2max~ trainability. We have reviewed 35 studies that have reported 97 genes associated with an exercise training-induced improvement in VO~2max~. It has been estimated that VO~2max~ trainability has a significant heritable component of around 50% \[[@CR39]\].

There were several studies that identified the same variant, including: the lipid-related *ACSL1*:c.-32-716 T \> C (rs6552828) \[[@CR20], [@CR21]\] and skeletal muscle-related *AMPD1*:c.133C \> T \[[@CR33], [@CR46]\]; intra-cellular calcium regulator *RYR2*:c.6166 + 552 T \> G; cellular function-related *CD44* (rs3653625), transcriptional activator *CAMTA1* (rs884736), non-coding *C12orf36* (rs12580476) and apoptotic regulator *20:g.63226200G \> A (*rs6090314) \[[@CR20], [@CR21]\]. Additionally, Bouchard et al. \[[@CR20]\] were able to replicate the variants in genes from the HERITAGE study, including: growth suppressor *NDN*, cell cortex function-related *DAAM1*, development-related *Z1C4* and signal transduction inhibitor *RGS18*. Numerous identified variants were found in pathways that contribute to training response (e.g. calcium signaling, immune function, angiogenesis, mitochondrial biogenesis) with pathways and associated SNPs possibly influencing each other and overall trainability \[[@CR21]\]. Several articles found conflicting results with electrolyte balance, lipid production and energy production genes *ACE* \[[@CR25], [@CR31], [@CR47], [@CR48]\], *APOE* \[[@CR13], [@CR23], [@CR41], [@CR42]\], *mtDNA* \[[@CR49], [@CR50]\] and *CKMM* variants respectively \[[@CR26], [@CR27], [@CR29], [@CR40]\]. All other 'predictor genes' identified are yet to be replicated.

While most of the articles examined in this review have focused on one or a few candidate genes/markers (*n* = 32), it is noted that exercise-related phenotypes are complex traits and are polygenic (i.e. influenced by many genes working together) with each genetic variant likely to be contributing a small percentage (typically less than 1%) to the overall change in VO~2max~ \[[@CR33], [@CR39], [@CR61]\]. Thus relying on one variant as a predictor is misguided; rather it has been suggested that a gene predictor score (GPS) based on numerous variants has a greater probability to determine higher and lower responders for VO~2max~ trainability. For example, a score of '0' represents a homozygote for a low-response variant; '1' represents heterozygous and '2' represents homozygous for a high-response variant \[[@CR20]\]. A higher score indicates a greater possible VO~2max~ training response (and vice versa). A similar model has been suggested in elite athletes aiming to determine the probability of an individual with a theoretically 'optimal' polygenic profile for endurance sports. The 'optimal' profile using a so-called 'total genotype score' (TGS, ranging from 0 to 100, with '0' and '100' being the worst and best genotype combinations, respectively) was quantified from a simple algorithm resulting from the combination of candidate polymorphisms \[[@CR62], [@CR63]\].

These predictor genes, along with muscle RNA and protein expression data provide a sound platform to further explore the cellular mechanisms underlying VO~2max~ trainability. Further research will need to consider several limitations identified from the literature to-date. For example, the lack of replication found between articles and conflicting results with certain variants, may be a result of several main limitations (typically in study design). Firstly, most of the articles used a hypotheses-driven candidate gene approach (*n* = 32), several articles used retrospective data from similar cohorts (*n* = 19), and many lacked a control group and randomization (*n* = 31). While it is understandable that in the past, high-throughput SNP microarray or gene sequencing technology was not available to use, by looking at one or only a few gene variants (whereas it is estimated that the human genome consists of about 40 million common gene variants) it is almost impossible to generate meaningful information. Similarly, a lack of control group makes it challenging to distinguish between individual response to an intervention and within-subject random variation \[[@CR64]\]. Secondly, most of the exercise training studies involve a relatively small number of participants (typically *n* = 20 to 30; with the exception of the HERITAGE and CARAGENE studies), which results in lack of statistical power when associating genotype with a phenotype. Many of the studies also failed to include a robust significance criterion (*p* \< 0.05 occurs approximately 10^6^ times in the genome by chance). Thirdly, a lack of racial diversity (74.5% Caucasian) further reduces the power of variants detected. Finally, many of the training studies were not tightly controlled in terms of nutrition, participant baseline data (study entry), physical activity status and other lifestyle factors.

Future research needs to consider epigenetic variation of gene activity that can occur in reaction to external factors, such as additional physical activity, drugs, diet and environmental toxins \[[@CR61], [@CR65]\]. Such epigenetic modifications can affect all adaptions to exercise training \[[@CR10]\]. For example, in addition to nutrition and baseline physical activity status, there were many other differences in subjects between articles not taken into consideration including: age, training duration and volume (MICT vs. HIIT), body weight, body fat percentage, medications, clinical versus healthy populations; sleep, psychological status and the gut microbiome. Together, these are potential epigenetic modifiers (e.g. DNA methylation and histone acetylation) that can influence gene expression, molecular function and thereby influence VO~2max~ training response \[[@CR61], [@CR66]\]. Whether genes or epigenetic modifiers play a larger percentage role in adaptive variability in a specific situation requires further exploration.

To address these limitations, larger-scale studies are required to ascertain if the 97 predictor genes identified from this review are similar in various cohorts (e.g. several ethnicities, ages, gender). The Athlome Project Consortium, which includes the Gene SMART study, is an example of a current larger-scale investigation examining 'omic markers' of training response, elite performance and injury rates/predisposition in variety of populations \[[@CR67]\]. Ideally, future studies will complement and expand on this research, and consider alternative forms of exercise training intensity and volume, lifestyle factors, general health, diet, medications and health history when implementing interventions and analyzing data.

Furthermore, the role of the gut microbiome, and its influence on metabolism and physiology, needs to be explored. For example, gut microbiota (which has its own genome) can interact with the tissue cellular environment to regulate gene expression \[[@CR61]\]. Poor diet, stress, illness, the use of antibiotics, environmental toxins and poor lifestyle choices can increase inflammation within the gut, causing dysbiosis; this appears to contribute to chronic diseases and other illnesses, irrespective of genotype, age and gender \[[@CR68], [@CR69]\]. Interestingly, VO~2max~ was recently shown to be related to gut microbial diversity in a human cross-sectional study \[[@CR70]\], suggesting a link between VO~2max~ and gut microbes. Pre- and probiotics, resistant starch and a Mediterranean diet (dietary diversification) can alter the gut microbiome \[[@CR68]\]. Investigating how the gut and human genome interact to positively influence VO~2max~ is warranted.

With these points in mind, the analysis of stool samples, in addition to incorporating epigenetic, transcription and proteomic analysis, may help to identify the best aerobic training or lifestyle intervention to upregulate or downregulate certain genes, signaling pathways and molecular responses required for a greater VO~2max~ training response. Implementing tightly-controlled studies examining various mediators (training intervention, diet, lifestyle) and molecular biomarkers across various populations will help to capture accurate information related to ideal traits for VO~2max~ trainability.

Conclusion {#Sec13}
==========

In total, 97 genes that predicted VO~2max~ trainability were identified. Phenotype is dependent on several of these genotypes/variants, which may contribute to approximately 50% of an individual's VO~2max~ trainability. Higher responders to exercise training have more positive response alleles (greater gene predictor score) than lower responders. Whilst these findings are exciting, further randomized-controlled research with larger and diverse cohorts are needed. Additional exploration is required to identify genetic variants and the mediators (training intensity and volume, diet, drugs, other lifestyle factors) that can potentially affect gene expression, molecular function and training response. Findings from this review and future research may assist clinicians to provide precision evidence-based medicine centered on phenotype, contributing to the fight against chronic disease.

Pubmed, embase, cinahl and cochrane search terms {#Sec14}
------------------------------------------------

### Pubmed search {#Sec15}

gene\*\[ti\] OR allele \[tiab\] OR SNP \[tiab\] OR genetic profiling\[tiab\] OR genetic variant\*\[tiab\] OR Genomic predictor\*\[tiab\] OR polymorphism\[tiab\] OR heritability\[tiab\] AND (exercise training \[tiab\] OR VO2peak\[tiab\] OR 'cardiorespiratory fitness'\[tiab\] OR 'maximal/maximum VO2peak'\[tiab\] OR maximal/maximum VO2max'\[tiab\] OR maximal oxygen consumption'\[tiab\]OR peak oxygen uptake'\[tiab\] OR interval exercise'\[tiab\] OR 'high/low intensity exercise'\[tiab\] OR peak fitness \[tiab\] OR endurance\*\[tiab\] OR physical fitness\[tiab\] OR cardiorespiratory fitness\[tiab\] OR endurance training \[tiab\] OR cardiovascular fitness\[tiab\] OR VO2max\[tiab\] OR aerobic power\[tiab\] OR aerobic fitness\[tiab\] OR exercise capacity\[tiab\] OR exercise training response\[tiab\] OR response to exercise training\[tiab\]) NOT animal\*.

### Embase {#Sec16}

gene:ab,ti OR allele:ab,ti OR snp:ab,ti OR 'genetic profiling':ab,ti OR 'genetic variant':ab,ti OR 'genomic predictor':ab,ti OR heritability:ab,ti AND (vo2peak:ab,ti OR vo2max:ab,ti OR 'cardiovascular fitness':ab,ti OR 'cardiorespiratory fitness':ab,ti OR 'aerobic power':ab,ti OR 'aerobic fitness':ab,ti OR 'exercise training response':ab,ti OR 'physical fitness':ab,ti).

### Cinahl {#Sec17}

(genes OR 'genetic variant' OR 'Genomic predictor' OR polymorphism OR 'genetic profiling' OR 'single nucleotide polymorphisms' OR 'SNPs' heritability) AND ('trainability' OR' cardiovascular fitness' OR 'interval exercise' OR 'maximum O2' OR maximal oxygen consumption' OR 'peak oxygen consumption' OR maximal aerobic capacity' OR 'high/low intensity exercise' OR 'cardiorespiratory fitness' OR 'aerobic power' OR 'response to exercise training' OR 'exercise capacity' OR 'VO2max' OR 'VO2peak' OR endurance).

### Cochrane database for systematic reviews {#Sec18}

(genes OR 'genetic variant' OR 'Genomic predictor' OR polymorphism OR 'genetic profiling' OR 'single nucleotide polymorphisms' OR 'SNPs' OR heritability) AND ('trainability' OR' cardiovascular fitness' OR 'interval exercise' OR 'maximum O2' OR maximal oxygen consumption' OR 'peak oxygen consumption' OR maximal aerobic capacity' OR 'high/low intensity exercise' OR 'cardiorespiratory fitness' OR 'aerobic power' OR 'response to exercise training' OR 'exercise capacity' OR 'VO2max' OR 'VO2peak' OR endurance).

### Cochrane central register of controlled trial {#Sec19}

(genes OR 'genetic variant' OR 'Genomic predictor' OR polymorphism OR 'genetic profiling' OR 'single nucleotide polymorphisms' OR 'SNPs' heritability) AND ('trainability' OR' cardiovascular fitness' OR 'cardiorespiratory fitness' OR 'interval exercise' OR 'maximum O2' OR maximal oxygen consumption' OR 'peak oxygen consumption' OR maximal aerobic capacity' OR 'high/low intensity exercise' OR 'aerobic power' OR 'response to exercise training' OR 'exercise capacity' OR 'VO2max' OR 'VO2peak' OR endurance).

Funding {#FPar1}
=======

Publication of this manuscript was supported by the Collaborative Research Network for Advancing Exercise and Sport Science (CRN-AESS).

Availability of data and materials {#FPar2}
==================================

The datasets supporting the conclusions of this article are included within the article.

About this supplement {#FPar3}
=====================

This article has been published as part of *BMC Genomics* Volume 18 Supplement 8, 2017: Proceedings of the 34th FIMS World Sports Medicine Congress. The full contents of the supplement are available online at <https://bmcgenomics.biomedcentral.com/articles/supplements/volume-18-supplement-8>.

CW was the primary author. MW checked the nomenclature of all variants and terminology used. JC, NE, UW, JL and KA provided expert advice and edits to the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate {#FPar4}
==========================================

Ethics approval from Bellberry.

Consent for publication {#FPar5}
=======================

Written informed consent was obtained from the individuals involved in this study.

Competing interests {#FPar6}
===================

The authors declare they have no competing interests.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
